BioRestorative Therapies (BRTX) S-1/A 5 Nov 15 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Entity Filer Category	Smaller Reporting Company
Document Type	S1
Amendment Flag	true
Document Period End Date	Jun. 30, 2015
Amendment Description	Updated to include material transactions subsequent to 6/30/15.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$ 6,445	$ 91,798	$ 201,098
Accounts receivable	50,982	0
Inventories	2,492	1,945	17,965
Prepaid expenses and other current assets	34,055	20,570	20,739
Deferred offering costs	152,167	0
Total Current Assets	246,141	114,313	239,802
Property and equipment, net	702,348	493,856	35,568
Intangible assets, net	1,076,189	1,037,732	1,107,545
Security deposit	45,900	45,900	0
Total Assets	2,070,578	1,691,801	1,382,915
Current Liabilities:
Accounts payable	1,746,614	1,111,879	1,269,970
Accrued expenses and other current liabilities	1,887,484	1,466,506	1,176,662
Accrued interest	56,027	94,026	65,909
Current portion of notes payable, net	1,115,319	5,688,239	4,990,009
Deferred revenues	114,118	164,349	0
Total Current Liabilities	4,919,562	8,524,999	7,502,550
Accrued interest, non-current portion	1,539	5,195	41,434
Notes payable, non-current portion	30,000	50,000	524,000
Total Liabilities	$ 4,951,101	$ 8,580,194	$ 8,067,984
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock	$ 0	$ 0	$ 0
Common stock	2,818	1,726	982
Additional paid-in capital	25,729,104	18,541,907	13,158,363
Accumulated deficit	(28,580,445)	(25,400,026)	(19,812,414)
Treasury stock, at cost	(32,000)	(32,000)	(32,000)
Total Stockholders' Deficiency	(2,880,523)	(6,888,393)	(6,685,069)
Total Liabilities and Stockholders' Deficiency	$ 2,070,578	$ 1,691,801	$ 1,382,915

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current portion of notes payable, debt discount	$ 81,366	$ 113,257	$ 237,381
Non-current portion of notes payable, debt discount		$ 0	$ 3,110
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, Authorized	5,000,000	5,000,000	5,000,000
Preferred stock, issued	0	0	0
Preferred stock, outstanding	0	0	0
Common stock, par value	$ 0.01	$ 0.001	$ 0.001
Common stock, Authorized	30,000,000	30,000,000	30,000,000
Common stock, Issued	2,818,363	1,725,596	981,662
Common stock, Outstanding	2,790,431	1,697,664	953,730
Treasury stock, at cost, shares	27,932	27,932	27,932

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenues	$ 333,666	$ 176,316	$ 415,996	$ 1,680
Cost of sales	151,077	42,426	213,834	208
Gross Profit	182,589	133,890	202,162	1,472
Operating Expenses
Marketing and promotion	94,028	47,329	125,626	114,951
Consulting	504,060	824,763	1,310,121	779,462
Research and development	859,344	787,071	1,430,614	1,594,054
General and administrative	1,613,927	1,184,632	2,258,307	2,265,275
Total Operating Expenses	3,071,359	2,843,795	5,124,668	4,753,742
Loss From Operations	(2,888,770)	(2,709,905)	(4,922,506)	(4,752,270)
Other (Expense) Income
Interest expense	(124,736)	(145,521)	(285,275)	(371,281)
Amortization of debt discount	(140,884)	(244,435)	(464,470)	(405,531)
Loss on extinguishment of notes payable, net	(26,029)	(49,094)	(49,094)	(7,200)
Warrant modification expense	0	(30,128)	(50,035)	(214,912)
Gain on settlement of payables	0	176,268	183,768	0
Total Other Expense	(291,649)	(292,910)	(665,106)	(998,924)
Net Loss	$ (3,180,419)	$ (3,002,815)	$ (5,587,612)	$ (5,751,194)
Net Loss Per Share
- Basic and Diluted (in dollars per share)	$ (1.60)	$ (2.79)	$ (4.38)	$ (6.96)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted (in shares)	1,993,544	1,077,606	1,276,904	826,340

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Treasury Stock
Balance at Dec. 31, 2012	$ (5,141,693)	$ 772	$ 8,950,755	$ (14,061,220)	$ (32,000)
Balance (in shares) at Dec. 31, 2012		772,175			(27,932)
Shares and warrants issued for cash	905,000	$ 42	904,958	0	$ 0
Shares and warrants issued for cash (in shares)		42,030			0
Shares and warrants issued as debt discount in connection with notes payable	573,769	$ 17	573,752	0	$ 0
Shares and warrants issued as debt discount in connection with notes payable (in shares)		16,938			0
Shares issued in satisfaction of accrued services	213,000	$ 14	212,986	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		13,313			0
Exercise of warrants for purchase of common stock	505,809	$ 84	505,725	0	$ 0
Exercise of warrants for purchase of common stock (in shares)		84,302			0
Shares and warrants issued in exchange of notes payable and accrued interest	417,681	$ 41	417,640	0	$ 0
Shares and warrants issued in exchange of notes payable and accrued interest (in shares)		40,925			0
Warrant modifications	214,912	$ 0	214,912	0	$ 0
Waiver of previously accrued executive salary and bonus	565,000	0	565,000	0	0
Beneficial conversion features related to convertible notes payable	0
Stock-based compensation: shares of common stock	138,055	$ 12	138,043	0	$ 0
Stock-based compensation: shares of common stock (in shares)		11,977			0
Stock-based compensation: options and warrants	674,592	$ 0	674,592	0	$ 0
Impact of share rounding as a result of reverse stock split	0	$ 0	0	0	$ 0
Impact of share rounding as a result of reverse stock split (in shares)		2			0
Net loss	(5,751,194)	$ 0	0	(5,751,194)
Balance at Dec. 31, 2013	(6,685,069)	$ 982	13,158,363	(19,812,414)	$ (32,000)
Balance (in shares) at Dec. 31, 2013		981,662			(27,932)
Shares and warrants issued for cash	2,605,000	$ 434	2,604,566	0	$ 0
Shares and warrants issued for cash (in shares)		433,600			0
Shares issued in satisfaction of accrued consulting services	140,000	$ 30	139,970	0	$ 0
Shares issued in satisfaction of accrued consulting services (in shares)		29,773			0
Shares and warrant issued as payment for leasehold improvements	71,050	$ 14	71,036	0	$ 0
Shares and warrant issued as payment for leasehold improvements (in shares)		14,210			0
Exercise of warrants for purchase of common stock	113,000	$ 19	112,981	0	$ 0
Exercise of warrants for purchase of common stock (in shares)		18,834			0
Conversion of notes payable and accrued interest into common stock	359,711	$ 89	359,622	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		89,239			0
Shares and warrants issued in exchange of notes payable and accrued interest	343,026	$ 55	342,971	0	$ 0
Shares and warrants issued in exchange of notes payable and accrued interest (in shares)		55,073			0
Shares and warrants issued in connection with extension of notes payable	249,800	$ 50	249,750	0	$ 0
Shares and warrants issued in connection with extension of notes payable (in shares)		50,000			0
Warrant modifications	50,035	$ 0	50,035	0	$ 0
Beneficial conversion features related to convertible notes payable	92,370	0	92,370	0	0
Stock-based compensation: shares of common stock	300,837	$ 53	300,784	0	$ 0
Stock-based compensation: shares of common stock (in shares)		53,205			0
Stock-based compensation: options and warrants	1,059,459	$ 0	1,059,459	0	$ 0
Net loss	(5,587,612)	0	0	(5,587,612)	0
Balance at Dec. 31, 2014	(6,888,393)	$ 1,726	18,541,907	(25,400,026)	$ (32,000)
Balance (in shares) at Dec. 31, 2014		1,725,596			(27,932)
Shares and warrants issued for cash	1,051,000	$ 180	1,050,820	0	$ 0
Shares and warrants issued for cash (in shares)		180,167			0
Shares issued in satisfaction of accrued services	8,481	$ 1	8,480	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		943			0
Conversion of notes payable and accrued interest into common stock	170,065	$ 35	170,030	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		34,869			0
Shares and warrants issued in connection with settlement agreement	152,000	$ 4	151,996	0	$ 0
Shares and warrants issued in connection with settlement agreement (in shares)		4,230			0
Warrants issued as debt discount in connection with notes payable	54,415	$ 0	54,415	0	$ 0
Shares and warrants issued in exchange of notes payable	5,142,065	$ 853	5,141,212	0	$ 0
Shares and warrants issued in exchange of notes payable (in shares)		853,360			0
Warrant modifications	15,900	$ 0	15,900	0	$ 0
Beneficial conversion features related to convertible notes payable	10,690	0	10,690	0	0
Stock-based compensation: shares of common stock	99,147	$ 19	99,128	0	$ 0
Stock-based compensation: shares of common stock (in shares)		19,198			0
Stock-based compensation: options and warrants	484,526	$ 0	484,526	0	$ 0
Net loss	(3,180,419)	0	0	(3,180,419)	0
Balance at Jun. 30, 2015	$ (2,880,523)	$ 2,818	$ 25,729,104	$ (28,580,445)	$ (32,000)
Balance (in shares) at Jun. 30, 2015		2,818,363			(27,932)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	$ (3,180,419)	$ (3,002,815)	$ (5,587,612)	$ (5,751,194)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	140,884	244,435	464,470	405,531
Accretion of interest expense	6,012	0	24,934	5,066
Depreciation and amortization	89,452	50,139	96,685	104,811
Loss on sale of property and equipment	0	1,009	1,009	0
Stock-based compensation	583,673	917,792	1,360,296	812,647
Loss on extinguishment of note payables, net	26,029	49,094	49,094	7,200
Gain on settlement of payables	0	(176,268)	(183,768)	0
Inventory write-down			15,407	0
Warrant modification expense	10,000	30,128	50,035	214,912
Warrant issued in connection with note payable			0	9,400
Changes in operating assets and liabilities:
Accounts receivable	(50,982)	0
Inventories	(547)	175	613	(5,481)
Prepaid expenses and other current assets	(13,485)	2,648	11,219	(2,306)
Security deposit			(45,900)	0
Accounts payable	313,352	(369,047)	(234,563)	498,541
Accrued interest, expenses and other current liabilities	641,873	267,810	585,881	1,028,469
Deferred revenues	(50,231)	224,975	164,349	0
Total Adjustments	1,696,030	1,242,890	2,359,761	3,078,790
Net Cash Used In Operating Activities	(1,484,389)	(1,759,925)	(3,227,851)	(2,672,404)
Cash Flows From Investing Activities
Purchases of property and equipment	(151,914)	0	(168,376)	(11,160)
Proceeds from sale of property and equipment	0	980	980	0
License maintenance costs	(75,000)	0
Net Cash (Used In) Provided By Investing Activities	(226,914)	980	(167,396)	(11,160)
Cash Flows From Financing Activities
Deferred offering costs	(8,050)	0
Proceeds from notes payable	515,000	670,000	795,000	1,454,000
Repayments of notes payable	0	(53,000)	(202,063)	(5,500)
Advances from director, officer and family member of officer	274,085	15,015	58,054	144,285
Repayment of advances from director and officer	(206,085)	(40,005)	(83,044)	(119,295)
Proceeds from exercise of warrants	0	80,000	113,000	505,809
Sales of common stock and warrants for cash	1,051,000	945,000	2,605,000	905,000
Net Cash Provided By Financing Activities	1,625,950	1,617,010	3,285,947	2,884,299
Net (Decrease) Increase In Cash	(85,353)	(141,935)	(109,300)	200,735
Cash - Beginning	91,798	201,098	201,098	363
Cash - Ending	6,445	59,163	91,798	201,098
Cash paid during the period for:
Interest	46,161	43,821	127,112	62,346
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	170,065	166,768	359,711	0
Accrued interest reclassified as principal in connection with note payable reissuance	0	73,058	108,059	68,100
Beneficial conversion features set up as debt discount	10,690	41,384	92,370	0
Waiver of previously accrued executive salary and bonus			0	565,000
Accrued liabilities associated with purchases of property and equipment	109,487	0	258,774	0
Accrued deferred offering costs	144,117	0
Indebtedness satisfied via legal settlement	5,000	0
Shares Issued in Connection with Notes Payable Extension
Non-cash investing and financing activities:
Shares issued			249,800	564,369
Shares and warrants issued in exchange for notes payable and accrued interest
Non-cash investing and financing activities:
Shares issued	5,116,036	343,026	0	213,000
Shares issued in satisfaction of accrued interest
Non-cash investing and financing activities:
Shares issued			343,026	417,681
Shares and warrant issued to satisfy lease obligation and leasehold improvements
Non-cash investing and financing activities:
Shares issued			71,050	0
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Shares issued	8,481	0	$ 140,000	$ 0
Warrant modification in connection with extension or exchanges of notes payable
Non-cash investing and financing activities:
Shares issued	5,900	0
Shares and warrants issued in connection with issuance or extension of notes payable
Non-cash investing and financing activities:
Shares issued	54,415	15,000
Shares And Warrants Issued In Connection With Settlement Agreement [Member]
Non-cash investing and financing activities:
Shares issued	$ 152,000	$ 0

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation BioRestorative Therapies, Inc. (together with its subsidiaries, “BRT” or the “Company”) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com D I S C www.stempearls.com The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2015 and for the six months ended June 30, 2015 and 2014. The results of operations for the six months ended June 30, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which are included elsewhere in this document. Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split 200,000,000 30,000,000	BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which the Company formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells designed for personal medical applications. BRT’s website is at www.biorestorative.com. BRT is currently pursuing a Disc/Spine Program. Its lead cell therapy candidate, brtxDISC™ ( D I S C www.stempearls.com . Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective April 15, 2013, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-50 reverse split 1,500,000,000 100,000,000 Note 1A – Reverse Stock Split Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock (the “July 2015 Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 30,000,000

Going Concern and Management Pl

Going Concern and Management Plans	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Development Stage Enterprise [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management Plans As of June 30, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $ 4,673,421 2,880,523 3,180,419 The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to June 30, 2015, (a) the Company has raised an aggregate of $ 335,000 585,015 410,000 65,512 412,685	Note 2 – Going Concern and Management’s Plans As of December 31, 2014, the Company had a working capital deficiency and a stockholders’ deficiency of $ 8,410,686 6,888,393 5,587,612 5,751,194 Despite recent revenue generated from specific research and development contracts, the Company's primary source of operating funds since inception has been, and will continue to be for the foreseeable future, equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to December 31, 2014, (a) the Company has raised an aggregate of $ 801,000 30,000 227,234 50,000 5,984 5,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Two pharmaceutical clients comprised substantially all of the Company’s revenue during the six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below. Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the six months ended June 30, 2015, the Company recognized revenue of $ 100,000 200,000 250,000 50,000 50,000 During the six months ended June 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $ 177,234 605,359 491,241 114,118 During the six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $ 327,466 175,025 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the six months ended June 30, 2015, the Company has recognized $ 6,000 During the six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 200 1,291 Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833 The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.	Note 3 – Summary of Significant Accounting Policies The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. As of December 31, 2014, 75 Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below. The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible. The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method. The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $ 15,407 Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 5 Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 17.7 20 2.3 Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses. Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $ 150,000 On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $ 250,000 89,063 130,068 During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $ 413,777 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. For the years ended December 31, 2014 and 2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 2,219 1,680 The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations. Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. December 31, 2014 2013 Options 779,200 252,150 Warrants 412,423 239,795 Convertible notes 32,695 53,169 Total potentially dilutive shares 1,224,318 545,111 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $ 15,280 25,748 Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $ 1,430,614 1,594,054 Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss. The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations. In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans. In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment December 31, 2014 2013 Office equipment $ 8,466 $ 7,670 Medical equipment 359,248 129,461 Furniture and fixtures 113,874 19,322 Computer software and equipment 66,458 20,169 Leasehold Improvements 103,582 - 651,628 176,622 Less: accumulated depreciation (157,772) (141,054) Property and equipment, net $ 493,856 $ 35,568 Depreciation expense amounted to $ 26,872 34,999

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Intangible Assets	Note 5 – Intangible Assets Patents and Accumulated Trademarks Licenses Amortization Total Balance as of January 1, 2013 $ 3,676 $ 1,226,500 $ (52,819) $ 1,177,357 Amortization expense - - (69,812) (69,812) Balance as of December 31, 2013 $ 3,676 $ 1,226,500 $ (122,631) $ 1,107,545 Amortization expense - - (69,813) (69,813) Balance as of December 31, 2014 $ 3,676 $ 1,226,500 $ (192,444) $ 1,037,732 Weighted average remaining amortization period at December 31, 2014 in years 6.0 14.9 Patents and Accumulated Trademarks Licenses Amortization Balance as of January 1, 2013 $ 736 $ 52,083 $ 52,819 Amortization expense 368 69,444 69,812 Balance as of December 31, 2013 $ 1,104 $ 121,527 $ 122,631 Amortization expense 368 69,445 69,813 Balance as of December 31, 2014 $ 1,472 $ 190,972 $ 192,444 Amortization expense is reflected in general and administrative expenses in the consolidated statements of operations. Based upon the current intangible assets as of December 31, 2014, amortization expense is projected to be approximately $ 70,000 On January 27, 2012, the Company entered into a license agreement with a stem cell treatment company (“SCTC”) (as amended on March 21, 2012, the “SCTC Agreement”). On April 6, 2012 (the “Closing Date”), the Company and SCTC closed on the SCTC Agreement. Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from SCTC to utilize or sublicense a certain medical device patent (pending) for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. The SCTC Agreement provides that the Company must achieve certain milestones. As of December 31, 2014, the Company had not met any the milestones provided for in the SCTC Agreement to be fulfilled by April 6, 2014; however, it still had the ability to pay $ 75,000 225,000 475,000 The SCTC Agreement also provides for an exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use for orthopedic purposes and a non-exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use (1) at a single facility in the Cayman Islands (or, under certain circumstances, at a different non-U.S. facility), and (2) at U.S. facilities (in accordance with protocols established by the Company), if and only if, upon resolution of a Food and Drug Administration (“FDA”) action, SCTC has the legal right to exploit the technology in the U.S. and the Company does not yet have such legal right. Further, the SCTC Agreement provides that SCTC will furnish certain training, assistance and consultation services with regard to the licensed technology. In addition, the Company had agreed to reimburse SCTC for 25 4,500 100,000 Pursuant to the SCTC Agreement, on the Closing Date, the Company made a payment to SCTC consisting of a license fee of $ 1,000,000 10,000 50,000 15,000 17,500 30.00 30.00 226,500 1,000,000 226,500 17.7 20 2.3 The Company has not made an accounting entry related to the second and third tranches as it is not currently estimable when the specified performance criteria will be met. When, and if, the second and third tranches of the SCTC Warrant vest (or when the timing of vesting becomes estimable), the grant date value of these tranches will be added to the value of the intangible asset after calculating the grant date values using the Black-Scholes option pricing model using the final exercise prices as inputs to the model.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities June 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,296 $ 4,739 Accrued payroll 860,253 679,277 Advances from related parties 68,000 - Accrued purchases of property and equipment 54,781 174,801 Accrued research and development expenses 401,175 292,395 Accrued general and administrative expenses 456,077 315,294 Deferred rent 43,902 - Total $ 1,887,484 $ 1,466,506 During the six months ended June 30, 2015, the Company received an aggregate of $ 274,085 206,085 68,000 15,015 40,005	Note 6 – Accrued Expenses and Other Current Liabilities December 31, 2014 2013 Credit card payable $ 4,739 $ 6,000 Accrued payroll and payroll taxes 679,277 672,535 Accrued purchases of property and equipment 174,801 - Accrued research and development expenses 292,395 229,276 Accrued general and administrative expenses 315,294 266,541 Deferred rent - 2,310 Total $ 1,466,506 $ 1,176,662 During the year ended December 31, 2014, the Company received an aggregate of $ 58,054 83,044 24,990 144,285 119,295

Notes Payable

Notes Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 315,000 244,000 - 559,000 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (158,333) - - (158,333) Recognition of debt discount - - - (115,005) [1] (115,005) Accretion of interest expense - - - 6,012 [1] 6,012 Amortization of debt discount - - - 140,884 140,884 Outstanding, June 30, 2015 $ - $ 315,000 [2] $ 911,685 $ (81,366) $ 1,145,319 [1] During the six months ended June 30, 2015, a note in the principal amount of $ 244,000 200,000 44,000 [2] As of June 30, 2015, convertible notes with an aggregate principal balance of $ 315,000 75,000 Bermuda Lender On May 11, 2015, Cayman and a lender to Cayman (the “Bermuda Lender”) agreed to extend the maturity date of a note with a principal balance of $ 410,938 316,297 On May 27, 2015, the Company and the Bermuda Lender agreed to exchange five notes (including the note referred to in the above paragraph) with an aggregate principal amount of $ 4,410,937 69,436 746,730 186,682 15.00 672,056 40,000 December 31, 2015 December 31, 2017 5,327 As of June 30, 2015, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock. Convertible Notes and Other Notes Issuances During the six months ended June 30, 2015, the Company issued convertible notes with an aggregate principal balance of $ 315,000 10 12 The convertible notes are convertible into shares of the Company's common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 62% to 65% of the fair value of the Company's common stock or (b) $3.00 per share. 17,700 10.00 54,415 During the six months ended June 30, 2015, the Company issued a six-month note payable with a principal amount of $244,000 for cash consideration of $200,000. The note bears no interest. The $44,000 difference between the principal amount of the note and the cash received was recorded as debt discount and is being amortized to interest expense over the term of the note. Conversions, Exchanges and Other During the six months ended June 30, 2015, pursuant to the original conversion terms of the convertible notes, the Company elected to convert convertible notes with an aggregate principal balance of $ 158,333 11,732 34,869 4.44 5.16 During the six months ended June 30, 2015, the Company exchanged a convertible note in the principal amount of $ 16,667 827 3,600 504 During the six months ended June 30, 2015, the Company elected to exchange notes payable with an aggregate principal balance of $ 592,874 25,296 103,030 25,756 15.00 92,725 15,249 20,197 During the six months ended June 30, 2015, the contingently adjustable conversion ratio associated with a certain convertible note was resolved. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the six months ended June 30, 2015, the Company recognized $ 10,690 41,384	Note 7 – Notes Payable Bermuda Convertible Other Debt Lender Notes Notes Discount Total Outstanding, December 31, 2012 $ 3,550,000 $ - $ 1,082,185 $ (76,719) $ 4,555,466 Issuances 450,000 281,000 [1] 733,000 - 1,464,000 Conversion of accrued interest - - 68,100 - 68,100 Exchanges for equity - - (404,285) - (404,285) Repayments - - (5,500) - (5,500) Recognition of debt discount - - - (574,369) [1] (574,369) Amortization of debt discount - - - 405,531 405,531 Accretion of interest expense - - - 5,066 [1] 5,066 Outstanding, December 31, 2013 $ 4,000,000 $ 281,000 $ 1,473,500 $ (240,491) $ 5,514,009 Issuances 500,000 300,000 [1] - - 800,000 Exchanges for equity - (71,000) (203,000) - (274,000) Conversions to equity - (342,500) - - (342,500) Repayments (89,063) - (113,000) - (202,063) Recognition of debt discount - - - (347,170) [1] (347,170) Amortization of debt discount - - - 464,470 464,470 Recharacterization of accrued interest as principal - - 108,059 [3] - 108,059 Accretion of interest expense - 15,000 [2] - 9,934 [1] 24,934 Settlement of accreted interest - (7,500) [2] - - (7,500) Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 [4] $ 1,265,559 $ (113,257) $ 5,738,239 [1] During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $ 30,000 60,000 25,000 50,000 5,000 10,000 [2] During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $ 90,000 105,000 15,000 7,500 30,000 [3] During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $ 108,059 752,500 860,559 [4] As of December 31, 2014, convertible notes with an aggregate principal balance of $ 175,000 83,333 Bermuda Lender On March 26, 2013, Cayman borrowed $ 450,000 3,550,000 4,000,000 July 31, 2014 450,000 213,000 30,000 480,000 20,000 50.00 250,000 13,313 457,826 11 On May 8, 2014, Cayman borrowed an additional $ 500,000 15 89,063 On August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of the $ 4,000,000 July 31, 2014 December 31, 2014 27,500 121,000 On December 31, 2014, Cayman and the Bermuda Lender agreed to further extend the maturity date of the $4,000,000 Bermuda Lender Note from December 31, 2014 June 30, 2015 22,500 99,000 As of December 31, 2014, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock. Convertible Notes Between August 8, 2013 and December 18, 2013, the Company issued convertible notes with an aggregate principal amount of $ 281,000 271,000 60,000 50,000 10,000 100 221,000 12 281,000 171,000 110,000 Between January 17, 2014 and May 2, 2014, the Company issued convertible notes with an aggregate principal amount of $ 175,000 170,000 30,000 25,000 5,000 145,000 12 The convertible notes were initially payable 3-12 months from the date of issuance 175,000 145,000 Between November 12, 2014 and December 2, 2014, the Company issued convertible notes in the aggregate principal amount of $ 125,000 10 41,667 41,667 41,666 During the year ended December 31, 2014, the Company elected to convert certain convertible notes with an aggregate principal balance of $ 225,000 13,565 60,138 2.80 5.60 During the year ended December 31, 2014, the holders of certain convertible notes elected to convert such convertible notes with an aggregate principal balance of $ 117,500 3,646 29,102 3.80 4.40 During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $ 71,000 4,260 12,339 5,000 15.00 74,029 1,231 During the year ended December 31, 2014, the contingently adjustable conversion ratios associated with certain convertible notes were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the year ended December 31, 2014, the Company recognized $ 92,370 Other Notes Other notes issued by the Company (“Other Notes”) predominantly bear interest at a rate of 15 The holders of two Other Notes are entitled to five years of royalty payments associated with Cosmetic Revenues, as defined in the notes, ranging from 0.5 4.0 100,000 In connection with the issuance and extension of Other Notes during the year ended December 31, 2013, the Company issued 5,000 3,704 20,125 18.80 50.00 112,239 In connection with the extension of Other Notes during the year ended December 31, 2014, the Company issued five-year warrants to purchase an aggregate of 9,500 10.00 15.00 29,800 During the year ended December 31, 2013, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $ 404,285 6,196 40,925 2,250 30.00 417,681 7,200 During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $ 203,000 15,672 42,735 5,000 15.00 268,997 50,325 During the year ended December 31, 2014, the Company repaid certain Other Notes with an aggregate principal balance of $ 113,000 11,219 See Note 11 – Subsequent Events for additional details regarding notes payable.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes For The Years Ended December 31, 2014 2013 United States $ (5,223,749) $ (5,328,958) Foreign (363,863) (422,236) Loss before income taxes $ (5,587,612) $ (5,751,194) The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2014 2013 Deferred Tax Assets: Net operating loss carryforward $ 4,820,500 $ 5,327,000 Stock-based compensation 1,272,600 907,100 Accruals 240,700 139,800 Research & development tax credits 95,500 - Other 2,100 2,700 Gross deferred tax assets 6,431,400 6,376,600 Deferred Tax Liabilities: Fixed assets (93,200) - Intangible assets (8,100) (3,000) Gross deferred tax liabilities (101,300) (3,000) Net deferred tax assets 6,330,100 6,373,600 Valuation allowance (6,330,100) (6,373,600) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (43,500) $ 1,631,300 For The Years Ended December 31, 2014 2013 Federal: Current $ - $ - Deferred 38,921 (1,459,584) State and local: Current - - Deferred 4,579 (171,716) 43,500 (1,631,300) Change in valuation allowance (43,500) 1,631,300 Income tax provision (benefit) $ - $ - For The Years Ended December 31, 2014 2013 Tax benefit at federal statutory rate (34.0) % (34.0) % State income taxes, net of federal benefit (4.0) % (4.0) % Permanent differences 0.8 % 5.8 % Research & development tax credits (1.8) % 0.0 % Impact of Section 382 limit 41.2 % 0.0 % True-ups and other (1.4) % 1.6 % Change in valuation allowance (0.8) % 30.6 % Effective income tax rate 0.0 % 0.0 % The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized. At December 31, 2014 and 2013, the Company had approximately $ 12,700,000 14,000,000 The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes. 50 approximately $5,700,000 of federal NOLs not being realizable the reversal of approximately $2,200,000 of net operating loss deferred tax assets. The Company files income tax returns in the U.S. federal jurisdiction and the states of Florida and New York, and is subject to examination by the various taxing authorities beginning with the tax years ended December 31, 2011.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Operating Lease During the six months ended June 30, 2015, the Company recognized approximately $ 64,000 14,000 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009 4,230 30,000 7.60 12.00 152,000 The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and a discretionary bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments of $ 150,000 ten 25,000 9.20 three 200,400 On March 9, 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $ 400,000 The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. 100,000 300,000 On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount currently $ 125,000 Board of Directors On April 6, 2015, the Company elected a new director to replace a director who had previously resigned. Concurrent with the election, the Company granted a ten 15,000 8.00 three 104,100	Note 9 – Commitments and Contingencies Operating Lease Jupiter, Florida Lease The Company was a party to a three year lease agreement with respect to premises located at the Alexandria Innovation Center in Jupiter, Florida, which was scheduled to expire on January 31, 2014 6,234 6,422 On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the leased premises and also extended the term of the lease to July 31, 2014. The amended lease provided for a base rent of $ 962 On February 11, 2014, the Company executed a Facility Use Agreement with the SCTC which permitted the Company to utilize the SCTC’s laboratory facility and one office for research associated with its culturing and medical device license. Payment terms were $ 3,750 100 On August 25, 2014, the Company entered into a lease for 6,800 132,600 149,260 In connection with the Melville Lease, the Company paid the landlord a cash security deposit of $ 45,900 14,210 7,105 10.00 71,050 60,000 11,050 Rent expense amounted to $ 20,380 99,175 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff is seeking to recover an unspecified amount of damages but at least approximately $ 193,000 4,000 The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Research Agreements Effective June 15, 2012, the Company entered into an assignment agreement (the “Assignment Agreement”) with the research foundation of a state university (the “Foundation”), whereby the Foundation assigned all of its right, title and interest in specified patents to the Company in exchange for a cash payment of $ 15,000 5 20 Effective June 15, 2012, the Company entered into a research agreement (the “Research Agreement”) with the same state university (the “University”). The Research Agreement has a term of three years. Pursuant to the Research Agreement, the University agreed to perform certain research services to be used by the Company. Pursuant to the Research Agreement, the Company agreed to pay the University a fee of $ 500,000 5 20 On May 9, 2014, the Company entered into an amendment to the Research Agreement. Pursuant to the amendment, the parties agreed that (i) no fees are payable by the Company to the University pursuant to the Research Agreement for the first five monthly payments in 2014 ($ 208,335 104,168 41,667 20,000 June 14, 2015 323,336 166,668 During the years ended December 31, 2014 and 2013, the Company recorded research and development expense of approximately $ 264,000 500,000 43,000 353,000 Consulting Agreements Marketing Consulting Services On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Marketing Consulting Term”). In consideration of services rendered during the New Marketing Consulting Term and the settlement of the Company’s obligation to pay $ 65,000 25,000 five 12,500 20.00 110,000 37,500 82,500 120,000 Consulting Services On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company’s Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $ 10,000 20,000 15,000 13.00 three 67,830 15,000 20,000 25,000 6.40 124,200 On March 12, 2014, as additional compensation for consulting services rendered, the Company granted to a consultant an immediately vested, five-year warrant to purchase 5,000 10.60 14,000 10.60 30.00 1,000 23,270 30,096 On July 23, 2014, the Company entered into a one-year agreement with a consultant to market research and development arrangements and other business transactions to potential strategic partners and other alliance candidates. In exchange for services provided by the consultant during the term, the Company agreed to issue 1,500 7,500 33,000 On October 7, 2014, the Company entered into an agreement with a consultant for services regarding the search for a President for the Company’s Disc/Spine Division. The consultant was entitled to an initial retainer fee of $ 15,000 10,000 28 25,000 2,420 15,000 Business Advisory Services On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $ 16,667 five 12,500 20.00 37,500 75,000 15,000 15,000 5,000 10.00 17,000 150,000 120,000 Scientific Advisory Services On March 27, 2013, the Company granted a ten 3,000 30.00 1,500 1,500 45,900 On June 10, 2013, the Company granted a five 250 20.00 2,056 On July 2, 2013, the Company granted a ten 5,000 20.00 2,500 2,500 47,960 On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new advisor a five 1,250 10.00 625 625 250 5,860 On June 27, 2014, an August 16, 2012 agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company’s Scientific Advisory Board, will earn $ 10,000 ten 15,000 5.70 7,500 7,500 81,000 Other On March 20, 2013, the Company granted an immediately vested, three-year warrant to purchase 500 30.00 6,600 On March 22, 2013, the Company granted an immediately vested, five-year warrant to purchase 5,000 80.00 59,000 On December 23, 2013, the Company granted immediately vested, five-year warrants to purchase an aggregate of 5,000 40.00 16,770 On July 22, 2014, the Company granted a consultant an immediately vested five-year warrant to purchase 500 15.00 1,500 In addition to the issuances discussed elsewhere in this filing, during the years ended December 31, 2014 and 2013, an aggregate of 23,719 6,477 159,837 77,555 Employment Agreements Chief Executive Officer Effective December 2013, the Company and its Chief Executive Officer (“CEO”) agreed that the CEO’s 2013 salary would be reduced from $ 600,000 360,000 300,000 25,000 565,000 During the year ended December 31, 2014, the Company and its CEO approved amendments to the employment agreement between the Company and the CEO, dated October 4, 2010, as amended, providing for (a) a reduction of the CEO’s annual salary from $ 600,000 450,000 450,000 400,000 450,000 600,000 As of December 31, 2014 and 2013, the accrued and unpaid compensation (salary, bonus, tax liability, car allowance and vacation pay) for the CEO was $ 574,278 542,535 Other In addition to the Company’s employment agreement with its CEO, as of December 31, 2014, two employees have “at-will” employment agreements with the Company that currently provide for aggregate cash severance payments of $ 175,000 Board of Directors On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $ 80,000 30,000 50,000 96,250 On June 27, 2014, the Company elected two new directors. Concurrent with the election, the Company granted the new directors ten-year options to purchase an aggregate of 30,000 5.70 10,000 10,000 10,000 144,000 As of December 31, 2014 and 2013, $ 105,000 130,000 Related Party Agreement Effective October 1, 2014, the Company entered into a three-month agreement with an affiliate of one of its directors for consulting services related to the Company’s brtxDISC™ Program and ThermoStem® Program. Pursuant to the agreement, the affiliate of the director was entitled to a cash fee of $ 10,000 5,000 36,786 15,000

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Authorized Capital On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000 5,000,000 Common Stock and Warrant Offerings During the six months ended June 30, 2015, the Company issued an aggregate of 180,167 5.00 6.00 1,051,000 56,290 8.00 188,883 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at annual rates ranging from 0 5 Stock Warrants For The Six Months Ended June 30, 2015 2014 Risk free interest rate 1.22% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 1.96 - 5.00 Expected volatility 121% - 122 % 120% - 129 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the six months ended June 30, 2015 was $ 3.60 3.80 On May 29, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 5,000 10,000 The Company recorded stock–based compensation expense of $ 0 167,126 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 316,428 13.82 Exercised - - Forfeited - - Outstanding, June 30, 2015 728,850 $ 16.17 3.8 $ 45,500 Exercisable, June 30, 2015 693,850 $ 15.47 3.9 $ 45,500 Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 3.9 32,500 7.60 25,000 4.8 25,000 8.00 12,500 4.5 12,500 10.00 56,554 4.6 56,554 10.60 19,000 2.9 19,000 11.60 2,500 4.3 2,500 12.00 5,000 4.8 5,000 15.00 454,638 4.0 454,638 18.80 2,500 4.3 2,500 20.00 27,500 3.9 27,500 30.00 43,140 2.0 43,140 35.00 1,000 1.8 1,000 40.00 6,176 3.4 6,176 50.00 1,000 2.1 1,000 60.00 1,842 2.8 1,842 80.00 3,000 2.3 3,000 Variable [1] 35,000 - - 728,850 3.9 693,850 [1] Warrants to purchase 35,000 30.00 Stock Options For the Six Months Ended June 30, 2015 2014 Risk free interest rate 1.33% - 1.64 % 1.50% - 2.54 % Expected term (years) 5.00 - 6.00 5.00 - 10.00 Expected volatility 121% - 122 % 120% - 121 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the options granted during the six months ended June 30, 2015 was $ 7.64 4.80 See Note 6 – Commitments and Contingencies – Employment Agreements for details associated with the grant of stock options in connection with employment agreements. On January 23, 2015, the Company granted five-year options to consultants to purchase an aggregate of 5,000 9.40 3,750 625 625 39,200 Weighted Average Remaining For The Six Months Ended Unrecognized at Amortization June 30, June 30, Period 2015 2014 2015 (Years) Consulting $ 118,230 $ 251,575 $ 476,246 2.3 Research and development 233,152 153,714 643,481 [1] 2.2 General and administrative 133,144 104,979 764,074 2.2 $ 484,526 $ 510,268 $ 1,883,801 2.2 [1] Includes $ 266,096 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 45,000 8.82 Exercised - - Forfeited (35,000) 6.34 Outstanding, June 30, 2015 789,200 $ 12.25 8.0 $ 317,000 Exercisable, June 30, 2015 365,327 $ 17.49 7.2 $ 28,500 Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 35,000 9.0 15,000 6.40 25,000 - - 6.60 281,250 4.2 3,750 6.80 12,500 - - 7.80 3,000 4.0 3,000 8.00 15,000 - - 9.20 25,000 - - 9.40 5,000 4.6 4,375 10.00 17,250 4.4 17,250 10.60 2,000 8.7 2,000 12.00 49,000 8.3 49,000 13.00 133,750 8.3 92,502 20.00 6,550 7.5 6,550 21.00 113,500 6.6 113,500 22.00 250 2.0 250 24.00 500 0.9 500 25.00 2,150 1.4 2,150 28.00 17,500 4.1 10,500 30.00 45,000 7.4 45,000 789,200 7.2 365,327 Compensatory Common Stock Issuances During the six months ended June 30, 2015, the Company issued an aggregate of 19,198 99,147 943 8,481 For The Six Months Ended Unrecognized at June 30, June 30, 2015 2014 2015 Consulting $ 90,300 $ 234,500 $ - Research and development 8,847 5,898 - $ 99,147 $ 240,398 $ -	Note 10 – Stockholders’ Deficiency Authorized Capital As of December 31, 2014, the Company was authorized to issue 100,000,000 0.001 1,000,000 0.01 On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 200,000,000 1,000,000 5,000,000 2010 Equity Participation Plan On February 18, 2014 and October 23, 2014, the Board of Directors of the Company approved successive increases in the number of shares of common stock authorized to be issued pursuant to the Plan from 300,000 600,000 1,000,000 1,000,000 Common Stock and Warrant Offerings During the year ended December 31, 2013, the Company issued an aggregate of 42,030 17.00 30.00 905,000 20,180 30.00 80.00 224,313 During the year ended December 31, 2014, the Company issued an aggregate of 433,600 5.00 9.00 2,605,000 116,535 6.00 15.00 389,608 See Note 7 – Notes Payable for details associated with common stock issued in conjunction with the extension and exchange of notes payable and related accrued interest. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with common stock issued in conjunction with consulting agreements. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0 5 Warrant Exercise and Reload Program On November 27, 2013, the Company initiated a limited time program (the “Warrant Exercise and Reload Program”) which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $ 6.00 15.00 The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $25.00 for five consecutive trading days. 18,834 84,302 113,000 505,809 50,035 214,912 Stock Warrants For The Year Ended December 31, 2014 2013 Risk free interest rate 0.39% - 2.20 % 0.34% - 1.68 % Expected term (years) 1.96 - 5.00 3.00 - 5.00 Expected volatility 116% - 122 % 132% - 135 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the years ended December 31, 2014 and 2013 was approximately $ 3.40 7.20 See Note 7 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 10 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings. The Company recorded stock–based compensation expense of $ 185,266 26,777 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2012 166,740 $ 33.80 Granted 157,357 31.20 Exercised (84,305) 6.00 [1] Forfeited - - Outstanding, December 31, 2013 239,792 $ 24.16 Granted 192,463 13.92 Exercised (18,832) 6.00 [1] Forfeited (1,000) 10.00 Outstanding, December 31, 2014 412,423 $ 17.97 3.2 $ - Exercisable, December 31, 2014 377,422 $ 16.86 3.3 $ - [1] During the year ended December 31, 2013, warrants to purchase an aggregate of 84,305 30.00 80.00 6.00 18,832 30.00 80.00 6.00 Warrants Outstanding Warrants Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 4.4 32,500 8.00 10,000 4.9 10,000 10.00 25,104 4.8 25,104 10.60 19,000 3.4 19,000 11.60 2,500 4.8 2,500 15.00 202,160 2.8 202,160 18.80 2,500 4.8 2,500 20.00 27,500 4.4 27,500 30.00 43,140 2.5 43,140 35.00 1,000 2.3 1,000 40.00 6,176 3.9 6,176 50.00 1,000 2.6 1,000 60.00 1,843 3.3 1,842 80.00 3,000 2.8 3,000 Variable [1] 35,000 - - 412,423 3.3 377,422 [1] Warrants to purchase 35,000 30.00 Stock Options For the Year Ended December 31, 2014 2013 Risk free interest rate 1.50% - 2.54 % 1.13% - 2.66 % Expected term (years) 5.00 - 10.00 5.00 - 10.00 Expected volatility 116% - 122 % 132% - 135 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the stock options granted during the years ended December 31, 2014 and 2013 was approximately $ 5.40 5.20 See Note 9 – Commitments and Contingencies for details associated with certain grants of options as compensation to employees, directors and consultants. On October 4, 2013, the Company granted ten-year options to employees, directors, and an advisor to purchase an aggregate of 49,000 12.00 24,500 24,500 199,921 Between February 18, 2014 and March 12, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 120,750 10.60 13.00 41,584 79,467 566,483 On June 16, 2014, the Company granted a five-year option to a consultant to purchase 3,000 7.80 18,600 On September 24, 2014, the Company granted a five-year option to a consultant to purchase 3,750 6.60 20,100 On October 23, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 297,500 6.60 1,710,400 On October 27, 2014, the Company granted a ten-year option to an advisor to purchase 12,500 6.80 78,500 On November 17, 2014, the Company granted a ten-year option to an employee to purchase 5,000 6.60 31,600 Weighted Average For the Year Ended Unrecognized at Amortization December 31, December 31, Period 2014 2013 2014 (Years) Consulting $ 365,825 $ 160,894 $ 654,956 2.6 Research and development 328,740 251,758 712,551 [1] 2.5 General and administrative 179,628 235,163 961,378 2.6 $ 874,193 $ 647,815 $ 2,328,885 2.6 [1] Includes $ 448,189 As of December 31, 2014, there was $ 2,328,885 2.6 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2012 200,900 $ 22.40 Granted 57,250 13.60 Exercised - - Forfeited (6,000) 10.00 Outstanding, December 31, 2013 252,150 $ 20.70 Granted 528,750 8.17 Exercised - - Forfeited (1,700) 26.18 Outstanding, December 31, 2014 779,200 $ 12.18 8.5 $ 979,600 Exercisable, December 31, 2014 318,573 $ 18.29 7.6 $ 45,600 Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 45,000 9.5 10,000 6.40 25,000 - - 6.60 306,250 4.7 3,750 6.80 12,500 - - 7.80 3,000 4.5 3,000 10.00 17,250 4.9 16,625 10.60 2,000 9.2 2,000 12.00 49,000 8.8 49,000 13.00 133,750 9.1 56,248 20.00 6,550 8.0 6,550 21.00 113,500 7.1 113,500 22.00 250 2.4 250 24.00 500 1.4 500 25.00 2,150 1.9 2,150 28.00 17,500 4.5 10,000 30.00 45,000 7.9 45,000 779,200 7.6 318,573 Compensatory Common Stock Issuances See Note 9 – Commitments and Contingencies for details associated with certain issuances of common stock as compensation to employees, directors and consultants. On October 4, 2013, the Company issued 2,500 12,500 Between June 27, 2014 and December 31, 2014, the Company issued 7,500 33,000 For the Year Ended Unrecognized at December 31, December 31, 2014 2013 2014 Consulting $ 276,500 $ 111,351 $ - Research and development 24,337 26,704 - $ 300,837 $ 138,055 $ - Weighted Average Total Number of Issuance Date Issuance Date Shares Fair Value Fair Value Non-vested, December 31, 2012 - $ - $ - Granted 11,977 11.53 138,055 Vested (11,977) (11.53) (138,055) Forfeited - - - Non-vested, December 31, 2013 - $ - $ - Granted 97,188 5.27 511,886 Vested (97,188) (5.27) (511,886) Forfeited - - - Non-vested, December 31, 2014 - $ - $ -

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Stock-based Compensation Subsequent to June 30, 2015, the Company issued an aggregate of 8,500 Subsequent to June 30, 2015, the Compensation Committee of the Board increased the number of shares authorized to be issued pursuant to the Plan from 1,000,000 2,000,000 Subsequent to June 30, 2015, the Company granted ten-year options to employees, directors, advisors and consultants to purchase an aggregate of 526,250 7.00 8.75 201,750 317,000 7,500 Common Stock and Warrant Offerings Subsequent to June 30, 2015, the Company issued an aggregate of 53,633 4.00 7.00 335,000 41,549 6.00 15.00 24,500 10.00 11.60 18.80 Stock Options On September 4, 2015, the Compensation Committee of the Board approved a resolution that, with respect to all outstanding options granted under the Plan, to the extent not already provided for in the stock option agreement evidencing the option grant, the optionee be given the right to exercise the option on a net exercise basis as contemplated by Section 13(b) of the Plan and, other than in the case of the Company’s CEO, in the event of a termination of employment, directorship, consultancy or membership on the Company’s Scientific Advisory Board, to the extent that the options are then exercisable, they shall remain exercisable until twelve months following such termination (unless the stock option agreement evidencing the option grant provides that such options are exercisable until the expiration date of the options), but in no event shall the options be exercisable after the respective expiration dates of the options. Short Term Advances Subsequent to June 30, 2015, the Company received an aggregate of $ 202,490 105,490 Notes Payable On July 7, 2015, pursuant to the provisions of a convertible note with a principal balance of $ 30,000 30,000 1,736 6,490 4.89 On July 9, 2015, the Company issued a convertible note in the principal amount of $ 100,000 10 The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “July Note First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the July Note First Maturity Date, (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the July Note First Maturity Date and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the July Note First Maturity Date. Each $25,000 of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Company’s stock or (b) $3.00 per share. 3,300 10.00 On July 27, 2015, the Company issued a six-month convertible note in the principal amount of $ 50,000 10 This note and the accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Company’s stock or $3.00 per share 1,500 10.00 On August 7, 2015, the Company issued a six-month convertible note in the principal amount of $ 50,000 10 This note and the accrued interest are convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Company’s stock or $3.00 per share 1,500 10.00 On August 13, 2015, the Company issued a convertible note in the principal amount of $ 60,000 50,000 1 The convertible note is payable as follows: (i) $20,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “August Note First Maturity Date”), (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the August Note First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the August Note First Maturity Date. Each $20,000 of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Company’s stock or (b) $3.00 per share. On August 19, 2015, the Company issued a six-month convertible note in the principal amount of $ 50,000 10 This note and the accrued interest are convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Company’s stock or $3.00 per share 1,885 10.00 On August 21, 2015, the Company issued a two-month note in the principal amount of $ 84,018 70,015 On September 29, 2015, the Company issued a one-month note payable to a family member of an officer of the Company in the principal amount of $ 75,000 65,000 On October 9, 2015, the Company issued a two-month note payable with a principal amount of $ 150,000 10 On October 14, 2015, the Company and certain lenders agreed to exchange notes with an aggregate principal amount of $ 840,000 70,727 227,682 227,682 4.00 460,000 6,951 116,738 116,738 4.00 380,000 63,776 110,944 110,944 4.00 Consulting Agreements On August 13, 2015, a February 17, 2011 agreement for business advisory services that had expired on June 30, 2015 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of July 1, 2015 and provided for an expiration date of June 30, 2016 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $ 15,000 10,000 12.00 10,000 10.00	Note 11 - Subsequent Events Research and Development Agreements; Bermuda Lender Subsequent to December 31, 2014, the Company received the third and fourth payments of four quarterly payments in the aggregate amount of $ 177,234 This payment triggered the mandatory principal prepayment of $ 177,237 266,297 Subsequent to December 31, 2014, the Company received payment in the amount of $ 50,000 Short Term Advances Subsequent to December 31, 2014, the Company received an aggregate of $ 60,055 60,055 Notes Payable Subsequent to December 31, 2014, the Company issued a convertible note with a principal amount of $ 30,000 12 55 2.00 Subsequent to December 31, 2014, the Company elected to convert a convertible note with a principal balance of $ 50,000 5,984 11,113 5.00 Notes payable, non-current portion represents notes payable that were either exchanged for equity or whose maturities were extended past December 31, 2015 after the balance sheet date but before the consolidated financial statements were issued. Accrued interest, non-current portion represents the accrued interest that, after the balance sheet date but before the consolidated financial statements were issued, was either exchanged for equity or converted into the principal amount of a note payable classified as non-current. Employment Agreements On February 9, 2015, the Company hired a President for its Disc/Spine Division. As compensation the Company granted to the President of its Disc/Spine Division a ten-year option to purchase 25,000 9.20 On March 9, 2015, the Company and the CEO agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $ 400,000 The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus). On March 9, 2015, the Company agreed to amend the at will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment of $ 125,000 Common Stock and Warrant Offerings Subsequent to December 31, 2014, the Company issued an aggregate of 135,167 5.00 9.20 801,000 42,542 8.00 15.00 4,000 15.00 Stock-Based Compensation Subsequent to December 31, 2014, the Company issued an aggregate of 13,515 73,528 On January 23, 2015, the Company granted a five-year option to consultants to purchase an aggregate 5,000 9.40 3,750 625 625

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.	Principles of Consolidation The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below.	Concentrations and Credit Risk As of December 31, 2014, 75 Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below.
Cash		Cash The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
Inventories		Inventories The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method. The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $ 15,407
Property and Equipment		Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 5
Intangible Assets		Intangible Assets Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 17.7 20 2.3
Impairment of Long-lived Assets		Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
Revenue Recognition	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the six months ended June 30, 2015, the Company recognized revenue of $ 100,000 200,000 250,000 50,000 50,000 During the six months ended June 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $ 177,234 605,359 491,241 114,118 During the six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $ 327,466 175,025 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the six months ended June 30, 2015, the Company has recognized $ 6,000 During the six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 200 1,291	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $ 150,000 On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $ 250,000 89,063 130,068 During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $ 413,777 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. For the years ended December 31, 2014 and 2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 2,219 1,680
Income Taxes		Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. December 31, 2014 2013 Options 779,200 252,150 Warrants 412,423 239,795 Convertible notes 32,695 53,169 Total potentially dilutive shares 1,224,318 545,111
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Advertising		Advertising Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $ 15,280 25,748
Research and Development		Research and Development Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $ 1,430,614 1,594,054
Reclassifications		Reclassifications Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
Convertible Instruments		Convertible Instruments GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
Recently Issued Accounting Pronouncements		Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations. In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans. In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2014 2013 Options 779,200 252,150 Warrants 412,423 239,795 Convertible notes 32,695 53,169 Total potentially dilutive shares 1,224,318 545,111

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment include the following: December 31, 2014 2013 Office equipment $ 8,466 $ 7,670 Medical equipment 359,248 129,461 Furniture and fixtures 113,874 19,322 Computer software and equipment 66,458 20,169 Leasehold Improvements 103,582 - 651,628 176,622 Less: accumulated depreciation (157,772) (141,054) Property and equipment, net $ 493,856 $ 35,568

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Schedule Of Intangible Assets By Major Class	Patents and Accumulated Trademarks Licenses Amortization Total Balance as of January 1, 2013 $ 3,676 $ 1,226,500 $ (52,819) $ 1,177,357 Amortization expense - - (69,812) (69,812) Balance as of December 31, 2013 $ 3,676 $ 1,226,500 $ (122,631) $ 1,107,545 Amortization expense - - (69,813) (69,813) Balance as of December 31, 2014 $ 3,676 $ 1,226,500 $ (192,444) $ 1,037,732 Weighted average remaining amortization period at December 31, 2014 in years 6.0 14.9
Schedule Of FiniteLived Intangible Assets Amortization Expense	Patents and Accumulated Trademarks Licenses Amortization Balance as of January 1, 2013 $ 736 $ 52,083 $ 52,819 Amortization expense 368 69,444 69,812 Balance as of December 31, 2013 $ 1,104 $ 121,527 $ 122,631 Amortization expense 368 69,445 69,813 Balance as of December 31, 2014 $ 1,472 $ 190,972 $ 192,444

Accrued Expenses and Other Cu22

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: June 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,296 $ 4,739 Accrued payroll 860,253 679,277 Advances from related parties 68,000 - Accrued purchases of property and equipment 54,781 174,801 Accrued research and development expenses 401,175 292,395 Accrued general and administrative expenses 456,077 315,294 Deferred rent 43,902 - Total $ 1,887,484 $ 1,466,506	Accrued expenses and other current liabilities are comprised of the following: December 31, 2014 2013 Credit card payable $ 4,739 $ 6,000 Accrued payroll and payroll taxes 679,277 672,535 Accrued purchases of property and equipment 174,801 - Accrued research and development expenses 292,395 229,276 Accrued general and administrative expenses 315,294 266,541 Deferred rent - 2,310 Total $ 1,466,506 $ 1,176,662

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 315,000 244,000 - 559,000 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (158,333) - - (158,333) Recognition of debt discount - - - (115,005) [1] (115,005) Accretion of interest expense - - - 6,012 [1] 6,012 Amortization of debt discount - - - 140,884 140,884 Outstanding, June 30, 2015 $ - $ 315,000 [2] $ 911,685 $ (81,366) $ 1,145,319 [1] During the six months ended June 30, 2015, a note in the principal amount of $ 244,000 200,000 44,000 [2] As of June 30, 2015, convertible notes with an aggregate principal balance of $ 315,000 75,000	A summary of the notes payable activity during the years ended December 31, 2014 and 2013 is presented below: Bermuda Convertible Other Debt Lender Notes Notes Discount Total Outstanding, December 31, 2012 $ 3,550,000 $ - $ 1,082,185 $ (76,719) $ 4,555,466 Issuances 450,000 281,000 [1] 733,000 - 1,464,000 Conversion of accrued interest - - 68,100 - 68,100 Exchanges for equity - - (404,285) - (404,285) Repayments - - (5,500) - (5,500) Recognition of debt discount - - - (574,369) [1] (574,369) Amortization of debt discount - - - 405,531 405,531 Accretion of interest expense - - - 5,066 [1] 5,066 Outstanding, December 31, 2013 $ 4,000,000 $ 281,000 $ 1,473,500 $ (240,491) $ 5,514,009 Issuances 500,000 300,000 [1] - - 800,000 Exchanges for equity - (71,000) (203,000) - (274,000) Conversions to equity - (342,500) - - (342,500) Repayments (89,063) - (113,000) - (202,063) Recognition of debt discount - - - (347,170) [1] (347,170) Amortization of debt discount - - - 464,470 464,470 Recharacterization of accrued interest as principal - - 108,059 [3] - 108,059 Accretion of interest expense - 15,000 [2] - 9,934 [1] 24,934 Settlement of accreted interest - (7,500) [2] - - (7,500) Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 [4] $ 1,265,559 $ (113,257) $ 5,738,239 [1] During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $ 30,000 60,000 25,000 50,000 5,000 10,000 [2] During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $ 90,000 105,000 15,000 7,500 30,000 [3] During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $ 108,059 752,500 860,559 [4] As of December 31, 2014, convertible notes with an aggregate principal balance of $ 175,000 83,333

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax effects of temporary differences that give rise to deferred tax assets	United States and foreign components of loss before income taxes were as follows: For The Years Ended December 31, 2014 2013 United States $ (5,223,749) $ (5,328,958) Foreign (363,863) (422,236) Loss before income taxes $ (5,587,612) $ (5,751,194) The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2014 2013 Deferred Tax Assets: Net operating loss carryforward $ 4,820,500 $ 5,327,000 Stock-based compensation 1,272,600 907,100 Accruals 240,700 139,800 Research & development tax credits 95,500 - Other 2,100 2,700 Gross deferred tax assets 6,431,400 6,376,600 Deferred Tax Liabilities: Fixed assets (93,200) - Intangible assets (8,100) (3,000) Gross deferred tax liabilities (101,300) (3,000) Net deferred tax assets 6,330,100 6,373,600 Valuation allowance (6,330,100) (6,373,600) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (43,500) $ 1,631,300
Income tax provision (benefit)	The income tax provision (benefit) consists of the following: For The Years Ended December 31, 2014 2013 Federal: Current $ - $ - Deferred 38,921 (1,459,584) State and local: Current - - Deferred 4,579 (171,716) 43,500 (1,631,300) Change in valuation allowance (43,500) 1,631,300 Income tax provision (benefit) $ - $ -
Reconciliation of effective tax rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For The Years Ended December 31, 2014 2013 Tax benefit at federal statutory rate (34.0) % (34.0) % State income taxes, net of federal benefit (4.0) % (4.0) % Permanent differences 0.8 % 5.8 % Research & development tax credits (1.8) % 0.0 % Impact of Section 382 limit 41.2 % 0.0 % True-ups and other (1.4) % 1.6 % Change in valuation allowance (0.8) % 30.6 % Effective income tax rate 0.0 % 0.0 %

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions: For The Six Months Ended June 30, 2015 2014 Risk free interest rate 1.22% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 1.96 - 5.00 Expected volatility 121% - 122 % 120% - 129 % Expected dividends 0.00 % 0.00 %	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For The Year Ended December 31, 2014 2013 Risk free interest rate 0.39% - 2.20 % 0.34% - 1.68 % Expected term (years) 1.96 - 5.00 3.00 - 5.00 Expected volatility 116% - 122 % 132% - 135 % Expected dividends 0.00 % 0.00 %
Summary of Warrant Activity	A summary of the stock warrant activity during the six months ended June 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 316,428 13.82 Exercised - - Forfeited - - Outstanding, June 30, 2015 728,850 $ 16.17 3.8 $ 45,500 Exercisable, June 30, 2015 693,850 $ 15.47 3.9 $ 45,500	A summary of the warrant activity during the years ended December 31, 2014 and 2013 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2012 166,740 $ 33.80 Granted 157,357 31.20 Exercised (84,305) 6.00 [1] Forfeited - - Outstanding, December 31, 2013 239,792 $ 24.16 Granted 192,463 13.92 Exercised (18,832) 6.00 [1] Forfeited (1,000) 10.00 Outstanding, December 31, 2014 412,423 $ 17.97 3.2 $ - Exercisable, December 31, 2014 377,422 $ 16.86 3.3 $ - [1] During the year ended December 31, 2013, warrants to purchase an aggregate of 84,305 30.00 80.00 6.00 18,832 30.00 80.00 6.00
Information Related to Stock Warrants	The following table presents information related to stock warrants at June 30, 2015: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 3.9 32,500 7.60 25,000 4.8 25,000 8.00 12,500 4.5 12,500 10.00 56,554 4.6 56,554 10.60 19,000 2.9 19,000 11.60 2,500 4.3 2,500 12.00 5,000 4.8 5,000 15.00 454,638 4.0 454,638 18.80 2,500 4.3 2,500 20.00 27,500 3.9 27,500 30.00 43,140 2.0 43,140 35.00 1,000 1.8 1,000 40.00 6,176 3.4 6,176 50.00 1,000 2.1 1,000 60.00 1,842 2.8 1,842 80.00 3,000 2.3 3,000 Variable [1] 35,000 - - 728,850 3.9 693,850 [1] Warrants to purchase 35,000 30.00	The following table presents information related to stock warrants at December 31, 2014: Warrants Outstanding Warrants Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 4.4 32,500 8.00 10,000 4.9 10,000 10.00 25,104 4.8 25,104 10.60 19,000 3.4 19,000 11.60 2,500 4.8 2,500 15.00 202,160 2.8 202,160 18.80 2,500 4.8 2,500 20.00 27,500 4.4 27,500 30.00 43,140 2.5 43,140 35.00 1,000 2.3 1,000 40.00 6,176 3.9 6,176 50.00 1,000 2.6 1,000 60.00 1,843 3.3 1,842 80.00 3,000 2.8 3,000 Variable [1] 35,000 - - 412,423 3.3 377,422 [1] Warrants to purchase 35,000 30.00
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions: For the Six Months Ended June 30, 2015 2014 Risk free interest rate 1.33% - 1.64 % 1.50% - 2.54 % Expected term (years) 5.00 - 6.00 5.00 - 10.00 Expected volatility 121% - 122 % 120% - 121 % Expected dividends 0.00 % 0.00 %	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Year Ended December 31, 2014 2013 Risk free interest rate 1.50% - 2.54 % 1.13% - 2.66 % Expected term (years) 5.00 - 10.00 5.00 - 10.00 Expected volatility 116% - 122 % 132% - 135 % Expected dividends 0.00 % 0.00 %
Stock option expense	The following table presents information related to stock option expense: Weighted Average Remaining For The Six Months Ended Unrecognized at Amortization June 30, June 30, Period 2015 2014 2015 (Years) Consulting $ 118,230 $ 251,575 $ 476,246 2.3 Research and development 233,152 153,714 643,481 [1] 2.2 General and administrative 133,144 104,979 764,074 2.2 $ 484,526 $ 510,268 $ 1,883,801 2.2 [1] Includes $ 266,096	The following table presents information related to stock option expense: Weighted Average For the Year Ended Unrecognized at Amortization December 31, December 31, Period 2014 2013 2014 (Years) Consulting $ 365,825 $ 160,894 $ 654,956 2.6 Research and development 328,740 251,758 712,551 [1] 2.5 General and administrative 179,628 235,163 961,378 2.6 $ 874,193 $ 647,815 $ 2,328,885 2.6 [1] Includes $ 448,189
Summary of Option Activity	A summary of the stock option activity during the six months ended June 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 45,000 8.82 Exercised - - Forfeited (35,000) 6.34 Outstanding, June 30, 2015 789,200 $ 12.25 8.0 $ 317,000 Exercisable, June 30, 2015 365,327 $ 17.49 7.2 $ 28,500	A summary of the option activity during the years ended December 31, 2014 and 2013 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2012 200,900 $ 22.40 Granted 57,250 13.60 Exercised - - Forfeited (6,000) 10.00 Outstanding, December 31, 2013 252,150 $ 20.70 Granted 528,750 8.17 Exercised - - Forfeited (1,700) 26.18 Outstanding, December 31, 2014 779,200 $ 12.18 8.5 $ 979,600 Exercisable, December 31, 2014 318,573 $ 18.29 7.6 $ 45,600
Information Related to Stock Options	The following table presents information related to stock options at June 30, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 35,000 9.0 15,000 6.40 25,000 - - 6.60 281,250 4.2 3,750 6.80 12,500 - - 7.80 3,000 4.0 3,000 8.00 15,000 - - 9.20 25,000 - - 9.40 5,000 4.6 4,375 10.00 17,250 4.4 17,250 10.60 2,000 8.7 2,000 12.00 49,000 8.3 49,000 13.00 133,750 8.3 92,502 20.00 6,550 7.5 6,550 21.00 113,500 6.6 113,500 22.00 250 2.0 250 24.00 500 0.9 500 25.00 2,150 1.4 2,150 28.00 17,500 4.1 10,500 30.00 45,000 7.4 45,000 789,200 7.2 365,327	The following table presents information related to stock options at December 31, 2014: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 45,000 9.5 10,000 6.40 25,000 - - 6.60 306,250 4.7 3,750 6.80 12,500 - - 7.80 3,000 4.5 3,000 10.00 17,250 4.9 16,625 10.60 2,000 9.2 2,000 12.00 49,000 8.8 49,000 13.00 133,750 9.1 56,248 20.00 6,550 8.0 6,550 21.00 113,500 7.1 113,500 22.00 250 2.4 250 24.00 500 1.4 500 25.00 2,150 1.9 2,150 28.00 17,500 4.5 10,000 30.00 45,000 7.9 45,000 779,200 7.6 318,573
Common Stock Award Expense	The following table presents information related to compensatory common stock expense: For The Six Months Ended Unrecognized at June 30, June 30, 2015 2014 2015 Consulting $ 90,300 $ 234,500 $ - Research and development 8,847 5,898 - $ 99,147 $ 240,398 $ -	The following table presents information related to compensatory common stock issuances expense during the years ended December 31, 2014 and 2013: For the Year Ended Unrecognized at December 31, December 31, 2014 2013 2014 Consulting $ 276,500 $ 111,351 $ - Research and development 24,337 26,704 - $ 300,837 $ 138,055 $ -
Summary of Common Stock Award Activity		A summary of compensatory common stock issuances activity during the years ended December 31, 2014 and 2013 is presented below: Weighted Average Total Number of Issuance Date Issuance Date Shares Fair Value Fair Value Non-vested, December 31, 2012 - $ - $ - Granted 11,977 11.53 138,055 Vested (11,977) (11.53) (138,055) Forfeited - - - Non-vested, December 31, 2013 - $ - $ - Granted 97,188 5.27 511,886 Vested (97,188) (5.27) (511,886) Forfeited - - - Non-vested, December 31, 2014 - $ - $ -

Business Organization, Nature26

Business Organization, Nature of Operations and Basis of Presentation - Additional Information (Detail) - shares	Jul. 07, 2015	Jul. 07, 2015	Apr. 15, 2013	Jun. 30, 2015	Jan. 01, 2015	Dec. 31, 2014	Dec. 19, 2014	Dec. 31, 2013
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio			the Company implemented a 1-for-50 reverse split
Stockholders equity note, changes in capital structure, retroactive impact			1,500,000,000 to 100,000,000
Changes in capital structure retroactive impact shares			1,500,000,000
Common stock, authorized			100,000,000	30,000,000	200,000,000	30,000,000		30,000,000
Subsequent Event [Member]
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio		the Company implemented a 1-for-20 reverse split
Changes in capital structure retroactive impact shares	200,000,000	200,000,000
Common stock, authorized	30,000,000	30,000,000			200,000,000		100,000,000

Going Concern and Management 27

Going Concern and Management Plans - Additional Information (Detail) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$ 4,673,421		$ 8,410,686
Stockholders deficiency	(2,880,523)		(6,888,393)	$ (6,685,069)	$ (5,141,693)
Net loss	(3,180,419)	$ (3,002,815)	(5,587,612)	(5,751,194)
Note principal and accrued interest converted to equity	(5,020,478)		(274,000)	$ (404,285)
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through equity financing	335,000		801,000
Amount raised through debt financing	585,015		30,000
Notes payable aggregate principal past due	412,685		5,000
Other Research and Development Expense			227,234
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	410,000		50,000
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$ 65,512		$ 5,984

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jul. 15, 2014	Mar. 24, 2014	Mar. 19, 2014	Apr. 06, 2012	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 20, 2015
Summary Of Significant Accounting Policies [Line Items]
Debt instrument outstanding face amount percentage									75.00%
Finite-Lived Intangible Asset, Useful Life				17 years 8 months 12 days
Advertising Expense									$ 15,280	$ 25,748
Research and Development Expense							$ 859,344	$ 787,071	$ 1,430,614	1,594,054
Finite Lived Intangible Asset Useful Life From Application Date									2 years 3 months 18 days
Deferred Revenue, Current							114,118		$ 164,349	0
Revenues							333,666	176,316	415,996	1,680
Cash Proceeds From Research Agreements	$ 89,063
Inventory Write-down									15,407	0
Accounts Receivable, Net, Current							50,982		0
sublicense agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized							6,000
Research and Development Agreements One Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms			Payment terms are (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet.
Deferred Revenue, Current									150,000
Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms		Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all three of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable.
Deferred Revenue, Current		$ 130,068							250,000
Cash Proceeds From Research Agreements					$ 89,063	$ 89,063
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues							327,466	175,025	$ 413,777
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life									3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life									5 years
Trademarks
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life									10 years
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenue, Net, Total									$ 2,219	$ 1,680
Revenues							200	$ 1,291
Licenses
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life									17 years 8 months 12 days
Patents
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life									20 years
Finite Lived Intangible Asset Useful Life From Application Date									2 years 3 months 18 days
Japanese Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized							100,000
Revenue Received							200,000
Deferred Revenue, Revenue Recognized							250,000
Accounts Receivable, Net, Current							50,000
Japanese Pharmaceutical Company [Member] | Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Accounts Receivable, Net, Current											$ 50,000
U.S. Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current							114,118
Revenue Received							605,359
Deferred Revenue, Revenue Recognized							491,241
U.S. Pharmaceutical Company [Member] | Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current							$ 177,234

Calculation of Weighted Average

Calculation of Weighted Average Dilutive Common Shares (Detail) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,583,769	825,833	1,224,318	545,111
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	789,200	435,450	779,200	252,150
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	728,850	316,283	412,423	239,795
Convertible notes
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	65,719	74,100	32,695	53,169

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$ 26,872	$ 34,999

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Office equipment		$ 8,466	$ 7,670
Medical equipment		359,248	129,461
Furniture and fixtures		113,874	19,322
Computer software and equipment		66,458	20,169
Leasehold Improvements		103,582	0
Property, Plant and Equipment, Gross		651,628	176,622
Less: accumulated depreciation		(157,772)	(141,054)
Property and equipment, net	$ 702,348	$ 493,856	$ 35,568

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	Mar. 05, 2015	Apr. 06, 2012	Jan. 27, 2012	Dec. 31, 2014	Oct. 07, 2014	Feb. 20, 2014
Finite-Lived Intangible Assets [Line Items]
Grant date value				$ 124,200	$ 15,000	$ 67,830
Payment capitalized as intangible asset		$ 1,000,000
Estimated useful life		17 years 8 months 12 days
Useful life lapsed since patent application				2 years 3 months 18 days
Amortization				$ 70,000
Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock				4,000
Exercise price of warrant				$ 15
Milestones payment	$ 75,000
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated useful life		20 years
First Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock		15,000
Exercise price of warrant		$ 30
Grant date value		$ 226,500
Payment capitalized as intangible asset		$ 226,500
Second Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock		17,500
Exercise price of warrant		$ 30
Maximum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment	475,000
Minimum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment	$ 225,000
License Agreement Terms
Finite-Lived Intangible Assets [Line Items]
Percentage of legal fees agreed to be reimbursed			25.00%
Net License fee paid		$ 1,000,000
Licenses Revenue		$ 10,000
Warrant Issued To Purchase Common Stock		50,000
License Agreement Terms | Maximum
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed			$ 100,000
License Agreement Terms | Maximum | Monthly Payment
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed			$ 4,500

Intangible Assets (Detail)

Intangible Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ 1,107,545	$ 1,177,357
Amortization expense	(69,813)	(69,812)
Ending Balance	1,037,732	1,107,545
Patents and Trademarks
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Amortization expense	0	0
Ending Balance	$ 3,676	3,676
Weighted Average Amortization Period	6 years
Licensing Agreements
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ 1,226,500	1,226,500
Amortization expense	0	0
Ending Balance	$ 1,226,500	1,226,500
Weighted Average Amortization Period	14 years 10 months 24 days
Accumulated Amortization
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$ (122,631)	(52,819)
Amortization expense	(69,813)	(69,812)
Ending Balance	$ (192,444)	$ (122,631)

Amortization of Intangible Asse

Amortization of Intangible Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Patents and Trademarks
Accumulated Amortization [Line Items]
Beginning Balance	$ 1,104	$ 736
Amortization expense	368	368
Ending Balance	1,472	1,104
Licensing Agreements
Accumulated Amortization [Line Items]
Beginning Balance	121,527	52,083
Amortization expense	69,445	69,444
Ending Balance	190,972	121,527
Accumulated Amortization
Accumulated Amortization [Line Items]
Beginning Balance	122,631	52,819
Amortization expense	69,813	69,812
Ending Balance	$ 192,444	$ 122,631

Accrued Expenses And Other Cu35

Accrued Expenses And Other Current Liabilities - Additional Information (Detail) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$ 274,085	$ 15,015	$ 58,054	$ 144,285
Repayment of advances from officer	206,085	$ 40,005	$ 83,044	119,295
Liability to officer	$ 68,000			$ 24,990

Accrued Expenses and Other Cu36

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 3,296	$ 4,739	$ 6,000
Accrued payroll	860,253	679,277	672,535
Advances from related parties	68,000	0
Accrued purchases of property and equipment	54,781	174,801	0
Accrued research and development expenses	401,175	292,395	229,276
Accrued general and administrative expenses	456,077	315,294	266,541
Deferred rent	43,902	0	2,310
Total	$ 1,887,484	$ 1,466,506	$ 1,176,662

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)		6 Months Ended			12 Months Ended
		Jun. 30, 2015		Jun. 30, 2014	Dec. 31, 2014		Dec. 31, 2013
Debt Instrument [Line Items]
Balance		$ 5,738,239		$ 5,514,009	$ 5,514,009		$ 4,555,466
Issuance		559,000			800,000		1,464,000
Indebtedness satisfied via settlement & Repayments		0		(53,000)	(202,063)		(5,500)
Exchanges to equity		(5,020,478)			(274,000)		(404,285)
Conversion to equity		(158,333)			(342,500)
Recognition of debt discount		(115,005)			(347,170)		(574,369)
Accretion of interest expense		6,012			24,934		5,066
Amortization of debt discount		140,884		244,435	464,470		405,531
Conversion of accrued interest							68,100
Recharacterization of accrued interest as principal					108,059
Settlement of accreted interest					(7,500)
Balance		1,145,319			5,738,239		5,514,009
Debt Discount
Debt Instrument [Line Items]
Balance		(113,257)		(240,491)	(240,491)		(76,719)
Issuance		0			0		0
Indebtedness satisfied via settlement & Repayments		0			0		0
Exchanges to equity		0			0		0
Conversion to equity		0			0
Recognition of debt discount		(115,005)	[1]		(347,170)	[2]	(574,369)	[2]
Accretion of interest expense		6,012	[1]		9,934	[2]	5,066	[2]
Amortization of debt discount		140,884			464,470		405,531
Conversion of accrued interest							0
Recharacterization of accrued interest as principal					0
Settlement of accreted interest					0
Balance		(81,366)			(113,257)		(240,491)
Convertible Notes
Debt Instrument [Line Items]
Balance		175,000	[3]	281,000	281,000		0
Issuance		315,000			300,000	[2]	281,000	[2]
Indebtedness satisfied via settlement & Repayments		0			0		0
Exchanges to equity		(16,667)			(71,000)		0
Conversion to equity		(158,333)			(342,500)
Recognition of debt discount		0			0		0
Accretion of interest expense		0			15,000	[4]	0
Amortization of debt discount		0			0		0
Conversion of accrued interest							0
Recharacterization of accrued interest as principal					0
Settlement of accreted interest	[4]				(7,500)
Balance		315,000	[5]		175,000	[3]	281,000
Other Notes
Debt Instrument [Line Items]
Balance		1,265,559		1,473,500	1,473,500		1,082,185
Issuance		244,000			0		733,000
Indebtedness satisfied via settlement & Repayments		(5,000)			(113,000)		(5,500)
Exchanges to equity		(592,874)			(203,000)		(404,285)
Conversion to equity		0			0
Recognition of debt discount		0			0		0
Accretion of interest expense		0			0	[6]	0
Amortization of debt discount		0			0		0
Conversion of accrued interest							68,100
Recharacterization of accrued interest as principal					108,059
Settlement of accreted interest					0
Balance		911,685			1,265,559		1,473,500
Bermuda Lender
Debt Instrument [Line Items]
Balance		4,410,937		$ 4,000,000	4,000,000		3,550,000
Issuance		0			500,000		450,000
Indebtedness satisfied via settlement & Repayments		0			(89,063)		0
Exchanges to equity		(4,410,937)			0		0
Conversion to equity		0			0
Recognition of debt discount		0			0		0
Accretion of interest expense		0			0		0
Amortization of debt discount		0			0		0
Conversion of accrued interest							0
Recharacterization of accrued interest as principal					0
Settlement of accreted interest					0
Balance		$ 0			$ 4,410,937		$ 4,000,000
[1]	During the six months ended June 30, 2015, a note in the principal amount of $244,000 bears no interest and was issued for cash consideration of $200,000. The $44,000 difference between the principal amount of the note and the cash received was recorded as debt discount and is being amortized to interest expense over the term of the note.
[2]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
[3]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
[4]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
[5]	As of June 30, 2015, convertible notes with an aggregate principal balance of $315,000 were convertible into shares of common stock at the election of the Company. Of such aggregate principal balance, under certain circumstances, the holder has the right to convert $75,000 in principal into shares of common stock.
[6]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $742,500 to $850,559.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail)	Aug. 13, 2014USD ($)shares	Jul. 15, 2014USD ($)	May. 27, 2015USD ($)$ / sharesshares	Dec. 02, 2014USD ($)	Mar. 26, 2013USD ($)$ / sharesshares	Mar. 31, 2015	May. 02, 2014USD ($)	Dec. 18, 2013USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Oct. 15, 2015	May. 29, 2015shares	May. 11, 2015USD ($)	May. 08, 2014USD ($)
Debt Instrument [Line Items]
Aggregate principal amount											$ 83,333
Rate of interest													10.00%
Warrants aggregate grant date fair value											389,608	$ 224,313
Debt instrument, face amount	$ 4,000,000										$ 7,500
Warrants to purchase common stock | shares											116,535	20,180
Loss on extinguishment of note payables, net									$ 26,029	$ 49,094	$ 49,094	$ 7,200
Accrued loan interest											108,059
Shares and warrants issued for cash (in shares) | shares	27,500
Common stock aggregate grant date fair value											74,029	3,704
Stock issued, amount									$ 1,051,000		$ 2,605,000	905,000
Warrant Issued During Period Relative Fair Value												$ 112,239
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									41,549		9,500	20,125
Debt Instrument Annual Principal Payment											$ 117,500
Debt Instrument Periodic Payment Interest											15,000
Debt Instrument, Periodic Payment, Principal											175,000
Proceeds from Notes Payable									$ 515,000	670,000	795,000	$ 1,454,000
Debt Instrument, Convertible, Beneficial Conversion Feature									10,690	41,384	$ 92,370	0
Debt Instrument, Interest Rate During Period											15.00%
Payments for royalties											$ 100,000
Debt Conversion, Original Debt, Amount											$ 30,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 15
Debt Instrument, Maturity Date Range, Start	Jul. 31, 2014										Dec. 31, 2014
Debt Instrument, Maturity Date Range, End	Dec. 31, 2014										Jun. 30, 2015
Amortization Of Debt Discount (Premium)									140,884	244,435	$ 464,470	405,531
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount											71,000
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount											$ 4,260
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable | shares											12,339
Warrants Issued During Period, Number of Warrants1 | shares											5,000
Payments under Research and Development Agreements											$ 113,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares											11,219
Cash Proceeds From Research Agreements		$ 89,063
Class of Warrant or Right, Outstanding | shares														5,000
Gains (Losses) On Extinguishment Of Debt									$ (26,029)	$ (49,094)	$ (49,094)	$ (7,200)
Class Of Warrant Or Rights Expiration Date			Dec. 31, 2017			Dec. 31, 2015
Warrants
Debt Instrument [Line Items]
Warrants aggregate grant date fair value											$ 29,800
Common Stock [Member]
Debt Instrument [Line Items]
Shares and warrants issued for cash (in shares) | shares									180,167		433,600	42,030
Stock issued, amount									$ 180		$ 434	$ 42
Debt Instrument, Convertible, Beneficial Conversion Feature									0		0
Notes Payable
Debt Instrument [Line Items]
Debt Instrument Annual Principal Payment											225,000
Debt Instrument, Increase, Accrued Interest											$ 13,565
Conversion of Stock, Shares Issued | shares											60,138
Notes Payable | Cayman
Debt Instrument [Line Items]
Debt instrument, face amount					$ 3,550,000
Other Notes Payable
Debt Instrument [Line Items]
Debt instrument, face amount									244,000
Amortization Of Debt Discount (Premium)									44,000
Proceeds from Convertible Debt									$ 200,000
First Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal				$ 41,667
Second Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal				41,667
Third Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal				$ 41,666
Scenario, Previously Reported [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									15,249
Minimum
Debt Instrument [Line Items]
Warrants exercise price | $ / shares											$ 6	$ 30
Debt Instrument, Periodic Payment, Principal											$ 752,500
Debt Instrument, Increase, Accrued Interest											$ 90,000
Percentage of royalty payments											0.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 10	18.80
Minimum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares											2.80
Maximum
Debt Instrument [Line Items]
Warrants exercise price | $ / shares											$ 15	80
Debt Instrument, Periodic Payment, Principal											$ 860,559
Debt Instrument, Increase, Accrued Interest											$ 105,000
Percentage of royalty payments											4.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 15	50
Maximum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 5.60
In exchange of notes payable
Debt Instrument [Line Items]
Warrants aggregate grant date fair value											$ 268,997
Warrants exercise price | $ / shares											$ 15	$ 30
Loss on extinguishment of note payables, net									$ 20,197		$ 50,325	$ 7,200
Shares and warrants issued for cash (in shares) | shares												5,000
Common stock aggregate grant date fair value												$ 417,681
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									25,756
Debt Conversion, Original Debt, Amount									$ 592,874
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 15
Amortization Of Debt Discount (Premium)									$ 0		0	0
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount											203,000	404,285
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount											$ 15,672	$ 6,196
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable | shares											42,735	40,925
Warrants Issued During Period, Number of Warrants1 | shares											5,000	2,250
Gains (Losses) On Extinguishment Of Debt									$ (20,197)		$ (50,325)	$ (7,200)
Debt Conversion, Converted Instrument, Shares Issued | shares									103,030
Accrued Interest Converted Into Stock									$ 25,296
Warrants and Rights Outstanding									92,725
Convertible Notes
Debt Instrument [Line Items]
Aggregate principal amount							$ 175,000	$ 281,000
Rate of interest				10.00%			12.00%	12.00%
Debt instrument, face amount									315,000
Loss on extinguishment of note payables, net									$ 504		1,231
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									17,700
Debt instrument conversion period description								The conversion price of the convertible notes is equal to the greater of (a) 55-65% (depending on the specific note) of the fair value of the Company’s common stock or (b) $1.00 per share. As of December 31, 2013, the convertible notes were not convertible. The Company evaluated the conversion options and determined that bifurcation was not necessary in accordance with ASC 815. The beneficial conversion features will be accounted for, if necessary, at the commitment date.
Debt instrument, new proceeds							$ 170,000	$ 271,000
Debt Instrument Unamortized Discount									$ 54,415
Debt Instrument Annual Principal Payment							30,000	60,000			30,000	60,000
Debt Instrument issued for consideration							25,000	50,000			25,000	50,000
Debt Instrument Periodic Payment Interest							5,000	10,000			5,000	10,000
Debt Instrument, Periodic Payment, Principal							$ 145,000	$ 221,000
Debt Instrument, Frequency of Periodic Payment							The convertible notes were initially payable 3-12 months from the date of issuance	Convertible Notes were initially payable 2-6 months from the date of issuance.
Proceeds from Notes Payable				$ 125,000			$ 175,000	$ 281,000
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 145,000	171,000
Debt Instrument Convertible Number of stock to holders								$ 110,000
Debt Instrument, Increase, Accrued Interest											3,646
Debt instrument, interest rate, effective percentage								100.00%
Debt Conversion, Original Debt, Amount									$ 158,333
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 10
Amortization Of Debt Discount (Premium)									$ 0		$ 0	$ 0
Conversion of Stock, Shares Issued | shares											29,102
Debt Instrument Issue Description							(a) 55%-60% (depending on the particular note) of the fair value of the Company’s stock or (b) $1.00 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $10.00 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $1.00 per share.
Proceeds from Convertible Debt									75,000
Gains (Losses) On Extinguishment Of Debt									$ (504)		$ (1,231)
Debt Instrument, Convertible, Terms of Conversion Feature									The convertible notes are convertible into shares of the Company's common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 62% to 65% of the fair value of the Company's common stock or (b) $3.00 per share.
Original Debt Accrued Interest Converted Into Stock									$ 11,732
Debt Conversion Original Debt Shares Issued | shares									34,869
Conversion Debt Accrued Interest Converted Into Stock									$ 827
Debt Conversion, Converted Instrument, Shares Issued | shares									3,600
Convertible Notes | Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount									$ 16,667
Convertible Notes | Minimum
Debt Instrument [Line Items]
Rate of interest									10.00%
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 4.44		$ 3.80
Convertible Notes | Maximum
Debt Instrument [Line Items]
Rate of interest									12.00%
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 5.16		$ 4.40
Waiver
Debt Instrument [Line Items]
Aggregate principal amount					450,000
Accrued loan interest					$ 213,000
Bermuda Lender
Debt Instrument [Line Items]
Aggregate principal amount																$ 500,000
Scheduled maturity date of the note					Jul. 31, 2014
Warrants aggregate grant date fair value					$ 457,826
Debt instrument, face amount			$ 4,410,937
Warrants to purchase common stock | shares					20,000
Warrants exercise price | $ / shares					$ 50
Loss on extinguishment of note payables, net									$ (5,327)
Shares and warrants issued for cash (in shares) | shares					30,000
Stock issued, amount					$ 480,000
Fair value Of warrants					$ 250,000
Stock issued during period shares in connection with accrued and unpaid interest | shares					13,313
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			186,682
Debt instrument, interest rate, effective percentage					11.00%											15.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 15
Amortization Of Debt Discount (Premium)	$ 121,000										$ 99,000
Debt Default, Short-term Debt, Amount															$ 316,297
Interest Payable			$ 69,436
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value			$ 672,056
Gains (Losses) On Extinguishment Of Debt									$ 5,327
Bermuda Lender | Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments			746,730
Class of Warrant or Right, Outstanding | shares									40,000
Bermuda Lender | Cayman
Debt Instrument [Line Items]
Aggregate principal amount											$ 22,500				$ 410,938
Bermuda Lender | Notes Payable | Cayman
Debt Instrument [Line Items]
Aggregate principal amount					$ 450,000
Debt instrument, face amount					$ 4,000,000

Loss before income taxes (Detai

Loss before income taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Before Income Tax Domestic And Foreign [Line Items]
United States	$ (5,223,749)	$ (5,328,958)
Foreign	(363,863)	(422,236)
Loss before income taxes	$ (5,587,612)	$ (5,751,194)

Deferred Tax Assets (Detail)

Deferred Tax Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Net operating loss carryforward	$ 4,820,500	$ 5,327,000
Stock-based compensation	1,272,600	907,100
Accruals	240,700	139,800
Research & development tax credits	95,500	0
Other	2,100	2,700
Gross deferred tax assets	6,431,400	6,376,600
Deferred Tax Liabilities:
Fixed assets	(93,200)	0
Intangible assets	(8,100)	(3,000)
Gross deferred tax liabilities	(101,300)	(3,000)
Net deferred tax assets	6,330,100	6,373,600
Valuation allowance	(6,330,100)	(6,373,600)
Deferred tax asset, net of valuation allowance	0	0
Changes in valuation allowance	$ (43,500)	$ 1,631,300

Income Tax Provision (benefit)

Income Tax Provision (benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current	$ 0	$ 0
Deferred	38,921	(1,459,584)
State and local:
Current	0	0
Deferred	4,579	(171,716)
Income tax provision (benefit) before change in valuation allowance	43,500	(1,631,300)
Change in valuation allowance	(43,500)	1,631,300
Income tax provision (benefit)	$ 0	$ 0

Statutory Federal Income Tax Ra

Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Tax benefit at federal statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(4.00%)	(4.00%)
Permanent differences	0.80%	5.80%
Research & development tax credits	(1.80%)	0.00%
Impact of Section 382 limit	41.20%	0.00%
True-ups and other	(1.40%)	1.60%
Change in valuation allowance	(0.80%)	30.60%
Effective income tax rate	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Federal and state net operating losses	$ 12,700,000	$ 14,000,000
Operating Loss Carry forwards Expiration Period	The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes.
Percentage of ownership changes	50.00%
Description for Section 382 limitation One	approximately $5,700,000 of federal NOLs not being realizable
Description for Section 382 limitation two	the reversal of approximately $2,200,000 of net operating loss deferred tax assets.

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Aug. 13, 2015USD ($)shares	Apr. 06, 2015USD ($)$ / sharesshares	Mar. 09, 2015USD ($)	Feb. 09, 2015USD ($)$ / sharesshares	Oct. 08, 2014USD ($)	Oct. 07, 2014USD ($)	Aug. 13, 2014shares	May. 09, 2014USD ($)	Mar. 14, 2014USD ($)$ / sharesshares	Mar. 12, 2014USD ($)$ / sharesshares	Feb. 11, 2014USD ($)	Feb. 04, 2014USD ($)	Jul. 02, 2013USD ($)$ / sharesshares	Jun. 10, 2013USD ($)$ / sharesshares	Oct. 04, 2010USD ($)	Jan. 23, 2015shares	Oct. 31, 2014USD ($)	Oct. 23, 2014USD ($)$ / sharesshares	Sep. 24, 2014USD ($)$ / sharesshares	Aug. 27, 2014USD ($)shares	Aug. 25, 2014USD ($)ft²$ / sharesshares	Jul. 27, 2014USD ($)$ / sharesshares	Jul. 23, 2014shares	Jul. 22, 2014USD ($)$ / sharesshares	Jun. 27, 2014USD ($)$ / sharesshares	Jun. 16, 2014USD ($)$ / sharesshares	Mar. 12, 2014USD ($)$ / sharesshares	Feb. 20, 2014USD ($)$ / sharesshares	Dec. 23, 2013USD ($)$ / sharesshares	Nov. 30, 2013USD ($)shares	Mar. 27, 2013USD ($)$ / sharesshares	Mar. 22, 2013USD ($)$ / sharesshares	Mar. 20, 2013USD ($)$ / sharesshares	Jun. 15, 2012USD ($)	Jan. 20, 2011	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Oct. 21, 2015$ / shares	Oct. 14, 2015$ / shares	May. 29, 2015shares
Commitments and Contingencies Disclosure [Line Items]
Grant date value						$ 15,000																						$ 67,830										$ 124,200
Warrant exercisable term																												3 years
Lease Expiration Date																																			Jan. 31, 2014
Lease Rent Second Year																																						6,234
Lease Rent Third Year																																						6,422
Research and Development Expense																																				$ 859,344	$ 787,071	1,430,614	$ 1,594,054
Accounts Payable and Accrued Liabilities, Total																																						$ 43,000	$ 353,000
Stock issued during period shares for services | shares																																				8,500
Stock issued during period, value, issued for services						2,420
Stock-based compensation, stock option granted | shares																												25,000								45,000		528,750	57,250
Common stock exercise price | $ / shares																												$ 6.40								$ 8.82		$ 8.17	$ 13.60
Number of shares called by warrants | shares																																				41,549		9,500	20,125
Initial year Salary						$ 25,000
Percentage Of Increase Salary						28.00%
Employee-related Liabilities																																						$ 574,278	$ 542,535
Salaries, Wages and Officers Compensation, Total																																							565,000
Loss Contingency, Damages Paid, Value																														$ 193,000
Loss contingency damages paid value, warrants issued | shares																														4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																						$ 15
Monthly Payments for Leasing												$ 962
Stock Issued During Period, Shares, New Issues | shares							27,500
Leasehold Improvements, Gross																																						$ 103,582	0
Rent Expense																																						20,380	99,175
Professional Fees																																				$ 504,060	824,763	1,310,121	779,462
Monthly Payments under Consulting Agreements						$ 15,000																$ 10,000
Monthly Escalating Payments under Consulting Agreements						$ 10,000
Warrants Issued During Period, Number of Warrants | shares																																				526,250
Share Based Compensation																																				$ 583,673	917,792	1,360,296	812,647
Security Deposit																																				45,900		$ 45,900	$ 0
Loss Contingency Damages Paid Value Per Year																														$ 52,000
Loss Contingency, Allegations																														The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
Operating Leases, Rent Expense, Net, Total																																				$ 64,000	$ 14,000
Class of Warrant or Right, Outstanding | shares																																										5,000
Warrants Issue One [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants | shares										5,000
Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares										$ 10.60																	$ 10.60
Warrants Issue Two [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants | shares										14,000
Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares										$ 10.60																	10.60
Warrants Issue Three [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants | shares										1,000
Warrants Issued During Period, Exercise Price at Issuance Date | $ / shares										$ 30																	$ 30
Chief Medical Advisor [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted | shares																												15,000
Common stock exercise price | $ / shares																												$ 13
Monthly Payments under Consulting Agreements					$ 15,000																							$ 10,000
Monthly Escalating Payments under Consulting Agreements					$ 20,000																							$ 20,000
Warrant [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value										$ 23,270																	$ 23,270
Allocated Share-Based Compensation Expense										$ 30,096
Common Stock [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, Other | shares																																						29,773
Stock Issued During Period, Shares, New Issues | shares																																				180,167		433,600	42,030
Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																																						4,000
Severance Costs			$ 125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																				$ 10				$ 4	$ 4
Warrants Issued During Period, Number of Warrants | shares																5,000
Class of Warrant or Right, Outstanding | shares																																				24,500
Minimum
Commitments and Contingencies Disclosure [Line Items]
Warrants exercise price | $ / shares																																						$ 6	$ 30
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																						10	18.80
Minimum | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																				$ 11.60
Maximum
Commitments and Contingencies Disclosure [Line Items]
Warrants exercise price | $ / shares																																						15	80
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																						$ 15	$ 50
Maximum | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																				$ 18.80
Legal Settlement Agreement [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues | shares																																				4,230
Loss Contingency, Allegations																																				The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009
Class of Warrant or Right, Outstanding | shares																																				30,000
Proceeds from Issuance of Warrants																																				$ 152,000
Legal Settlement Agreement [Member] | Minimum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																				$ 7.60
Legal Settlement Agreement [Member] | Maximum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																				$ 12
Director
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																									30,000
Grant date value																									$ 144,000
Stock-based compensation, stock option granted | shares		15,000
Common stock exercise price | $ / shares		$ 8
Stock options granted exercise price per share | $ / shares																									$ 5.70
Number of shares vest on first anniversary of date of grant | shares																									10,000
Number of shares vest on second anniversary of date of grant | shares																									10,000
Number Of Shares Vest On Third Anniversary Of Date Of Grant | shares																									10,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		10 years
Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value		$ 104,100
Chief Executive Officer
Commitments and Contingencies Disclosure [Line Items]
Employee-related Liabilities																																							$ 25,000
Salaries, Wages and Officers Compensation, Total			400,000												$ 600,000																							$ 450,000	600,000
Salary Reduced																																						450,000	360,000
Salary Bonus																																							300,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount			$ 100,000
Chief Executive Officer | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total																																						450,000
Salary Reduced																																						400,000
Chief Executive Officer | Minimum | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues | shares																																				1,000,000
Chief Executive Officer | Maximum | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues | shares																																				2,000,000
Consultant
Commitments and Contingencies Disclosure [Line Items]
Stock issued during period shares for services | shares																							1,500
Stock issued during period, value, issued for services																																						$ 33,000
Stock-based compensation, stock option granted | shares																			3,750							3,000
Common stock exercise price | $ / shares																			$ 6.60							$ 7.80
Number of shares immediately vest on date of grants | shares																																						7,500
Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value																			$ 20,100							$ 18,600
Non Employee Director Awards
Commitments and Contingencies Disclosure [Line Items]
Accounts Payable and Accrued Liabilities, Total																																						$ 105,000	130,000
Board of Directors
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total																									$ 80,000
Compensation Paid To Directors Aggregate Amount																									30,000
Compensation Paid To Directors Installment Amount																									50,000
Share Based Compensation																									$ 96,250
Employees and Directors
Commitments and Contingencies Disclosure [Line Items]
Grant date value																																						$ 15,000
Stock issued during period, value, issued for services																	$ 5,000
Stock-based compensation, stock option granted | shares																		297,500									120,750											36,786
Common stock exercise price | $ / shares																		$ 6.60
Monthly Payments under Consulting Agreements																	$ 10,000
Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value																		$ 1,710,400
Employees and Directors | Minimum
Commitments and Contingencies Disclosure [Line Items]
Common stock exercise price | $ / shares																											$ 10.60
Employees and Directors | Maximum
Commitments and Contingencies Disclosure [Line Items]
Common stock exercise price | $ / shares																											$ 13
President [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted | shares				25,000
Common stock exercise price | $ / shares				$ 9.20
Severance Costs				$ 150,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value				$ 200,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Deferred Compensation Arrangement with Individual, Description			The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Companys Compensation Committee, are satisfied.
Business Advisory Services
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted | shares																				15,000
Business Advisory Services | Extension 1
Commitments and Contingencies Disclosure [Line Items]
Warrant exercisable term																						5 years
Marketing Consulting Services
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																						12,500
Exercise price of warrant | $ / shares																						$ 20
Marketing Consulting Services | Consultant
Commitments and Contingencies Disclosure [Line Items]
Contractual Obligation																						$ 65,000
Consulting Expense In Shares | shares																						25,000
Business Advisory Services Immediately Vesting
Commitments and Contingencies Disclosure [Line Items]
Consulting expense																				$ 75,000
August 16, 2015
Commitments and Contingencies Disclosure [Line Items]
Number of shares vest on first anniversary of date of grant | shares																									7,500
August 16, 2016
Commitments and Contingencies Disclosure [Line Items]
Number of shares vest on second anniversary of date of grant | shares																									7,500
Assignment Agreement
Commitments and Contingencies Disclosure [Line Items]
Cash payment in exchange for patents																																		$ 15,000
Percentage of royalty agreed to be paid																																		5.00%
Royalty Period																																		20 years
Research and Development Arrangement
Commitments and Contingencies Disclosure [Line Items]
Cash payment in exchange for patents																																		$ 500,000
Percentage of royalty agreed to be paid																																		5.00%
Royalty Period																																		20 years
Research and Development Expense																																						$ 264,000	500,000
Professional Fees								$ 208,335																														323,336
Accrued Professional Fees								104,168
Gain On Settlement Related To Agreement								$ 166,668
Agreement Expiration Date								Jun. 14, 2015
Research and Development Arrangement | Minimum
Commitments and Contingencies Disclosure [Line Items]
Fees payable for services per month								$ 20,000
Research and Development Arrangement | Maximum
Commitments and Contingencies Disclosure [Line Items]
Fees payable for services per month								$ 41,667
Marketing Consulting Services Agreement
Commitments and Contingencies Disclosure [Line Items]
Warrant exercisable term																									5 years
Consulting expense																																						82,500	120,000
Marketing Consulting Services Agreement | Warrant [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value																						$ 37,500
Marketing Consulting Services Agreement | Common Stock [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value																						$ 110,000
Business Advisory Services | Extension 1
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																						12,500
Exercise price of warrant | $ / shares																						$ 20
Grant date value																						$ 37,500
Additional Monthly Fee For Services Rendered																						$ 16,667
Business Advisory Services | Extension 1 | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares	10,000
Additional Monthly Fee For Services Rendered	$ 15,000
Business Advisory Services | Extension 2
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																						5,000
Exercise price of warrant | $ / shares																						$ 10
Grant date value																						$ 17,000
Additional Monthly Fee For Services Rendered																						$ 15,000
Consulting expense																																						150,000	$ 120,000
Business Advisory Services | Extension 2 | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares	10,000
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Restructuring Reserve, Current																																						$ 175,000
Severance Costs			$ 125,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount			$ 300,000
Scientific Advisory Services
Commitments and Contingencies Disclosure [Line Items]
Grant date value									$ 5,860				$ 47,960																		$ 45,900
Warrant exercisable term									5 years				10 years	5 years											10 years						10 years
Recognized granted fair value award														$ 2,056
Total options granted | shares									1,250				5,000	250								15,000									3,000
Stock options granted exercise price per share | $ / shares									$ 10				$ 20	$ 20								$ 5.70									$ 30
Number of shares immediately vest on date of grants | shares									250													81,000									1,500
Number of shares vest on first anniversary of date of grant | shares									625				2,500
Number of shares vest on second anniversary of date of grant | shares									625				2,500																		1,500
Other
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock | shares																								500					5,000			5,000	500
Grant date value																								$ 1,500					$ 16,770			$ 59,000	$ 6,600
Warrant exercisable term																								5 years					5 years			5 years	3 years
Additional vested common stock shares | shares																																						23,719	6,477
Additional Vested Common Stock Value																																						$ 159,837	$ 77,555
Warrants exercise price | $ / shares																								$ 15					$ 40			$ 80	$ 30
Stem Cell Treatment Company
Commitments and Contingencies Disclosure [Line Items]
Monthly Payments for Leasing											$ 100
Payments for Leasing Per Day											$ 3,750
Melville Lease
Commitments and Contingencies Disclosure [Line Items]
Number of shares called by warrants | shares																					7,105
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																					$ 10
Land Subject to Ground Leases | ft²																					6,800
Land Lease Term																					63 months
Stock Issued During Period, Shares, Other | shares																					14,210
Description Of Leasing Arrangement Consideration																					(i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease.
Stock Issued During Period, Shares, New Issues | shares																																						71,050
Leasehold Improvements, Gross																																						$ 60,000
Prepaid Rent																																						11,050
Security Deposit																																						$ 45,900
Melville Lease | Minimum
Commitments and Contingencies Disclosure [Line Items]
Accrued Rent																					$ 132,600
Melville Lease | Maximum
Commitments and Contingencies Disclosure [Line Items]
Accrued Rent																					$ 149,260

Stockholders' Deficiency - Addi

Stockholders' Deficiency - Additional Information (Detail) - USD ($)	Oct. 07, 2014	Aug. 13, 2014	Oct. 04, 2013	Jan. 23, 2015	Nov. 17, 2014	Oct. 31, 2014	Oct. 27, 2014	Oct. 23, 2014	Sep. 24, 2014	Jul. 23, 2014	Jun. 16, 2014	Mar. 12, 2014	Feb. 20, 2014	Nov. 27, 2013	Jun. 30, 2015	Dec. 30, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Oct. 21, 2015	Oct. 15, 2015	Oct. 14, 2015	Aug. 13, 2015	Jul. 07, 2015	May. 29, 2015	Jan. 01, 2015	Dec. 19, 2014	May. 08, 2014	Feb. 18, 2014	Apr. 15, 2013
Stockholders Equity Note Disclosure [Line Items]
Shares and warrants issued for cash (in shares)		27,500
Sales of common stock and warrants for cash															$ 1,051,000		$ 945,000	$ 2,605,000	$ 905,000
Warrants to purchase common stock																		116,535	20,180
Warrants aggregate grant date fair value																		$ 389,608	$ 224,313
Share granted vested			24,500									41,584			625
Weighted average estimated fair value of stock options granted															$ 7.64		$ 4.80	$ 5.40	$ 5.20
Stock-based compensation, stock option granted													25,000		45,000			528,750	57,250
Stock-based compensation, stock options granted, exercise price													$ 6.40		$ 8.82			$ 8.17	$ 13.60
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued															19,198
Grant date fair value															$ 99,147
Common stock, Authorized															30,000,000			30,000,000	30,000,000							200,000,000				100,000,000
Common stock, par value															$ 0.01			$ 0.001	$ 0.001
Preferred stock, Authorized															5,000,000			5,000,000	5,000,000							5,000,000	1,000,000
Preferred stock, par value															$ 0.01			$ 0.01	$ 0.01
Proceeds from Warrant Exercises															$ 0		$ 80,000	$ 113,000	$ 505,809
Warrant modification charge															15,900			50,035	$ 214,912
Warrant redemption terms														The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $25.00 for five consecutive trading days.
Received non-interest bearing advances from officer																		60,055
Repayments Short Term Advances																		60,055
Debt Instrument, Face Amount		$ 4,000,000																7,500
Warrant Or Right Expense Or Revenue Recognized															$ 10,000
Class of Warrant or Right, Outstanding																									5,000
Stock Issued During Period, Shares, Issued for Services															8,500
Stock Issued During Period, Value, Issued for Services	$ 2,420
Bermuda Lender [Member] | Research and Development Arrangement [Member]
Stockholders Equity Note Disclosure [Line Items]
Debt Instrument Prepayments of Debt																		266,297
Debt Instrument, Face Amount																												$ 177,237
Subsequent Event [Member]
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																								30,000,000		200,000,000	100,000,000
Preferred stock, Authorized																										5,000,000
Debt Instrument, Face Amount																		$ 50,000		$ 460,000	$ 150,000	$ 840,000	$ 60,000
Class of Warrant or Right, Outstanding															24,500
Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price														$ 6
Exercise price of redeemable warrant to be issued														$ 15
Warrants excluded from computation of weighted average price of warrants granted																		18,832
Exercise Price Dollor One Point Five Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted																		35,000
Share based compensation shares authorized under stock option plans exercise price																		$ 30
Exercise Price Dollor One Point Five Zero | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted																			84,305
Exercise Price Dollor Zero Point Three Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted															35,000			18,834	84,302
Share based compensation shares authorized under stock option plans exercise price															$ 30
Legal Counsel
Stockholders Equity Note Disclosure [Line Items]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued			2,500													7,500
Grant date fair value			$ 12,500													$ 33,000
First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested			24,500
Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested												79,467
Employee
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted					5,000
Stock-based compensation, stock options granted, exercise price					$ 6.60
Stock-based compensation, stock options granted, grant date fair value					$ 31,600
Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted							12,500
Stock-based compensation, stock options granted, exercise price							$ 6.80
Stock-based compensation, stock options granted, grant date fair value							$ 78,500
Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted								297,500				120,750						36,786
Stock-based compensation, stock options granted, exercise price								$ 6.60
Stock-based compensation, stock options granted, grant date fair value								$ 1,710,400
Stock Issued During Period, Value, Issued for Services						$ 5,000
Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted			49,000
Stock-based compensation, stock options granted, exercise price			$ 12
Consultant [Member]
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted									3,750		3,000
Stock-based compensation, stock options granted, exercise price									$ 6.60		$ 7.80
Stock-based compensation, stock options granted, grant date fair value									$ 20,100		$ 18,600
Stock Issued During Period, Shares, Issued for Services										1,500
Stock Issued During Period, Value, Issued for Services																		$ 33,000
Professional Services [Member]
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services															943
Stock Issued During Period, Value, Issued for Services															$ 8,481
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share															$ 3.60		$ 3.80	$ 3.40	$ 7.20
Warrants | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price																		$ 6	$ 6
Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense															$ 484,526		$ 510,268	$ 874,193	$ 647,815
Unrecognized stock-based compensation expense																		$ 2,328,885
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition															2 years 2 months 12 days			2 years 7 months 6 days
Consultant Awards | First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested															3,750
Consultant Awards | Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested															625
Consultant Awards | Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted				5,000
Stock-based compensation, stock options granted, exercise price				$ 9.40
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense															$ 0		$ 167,126	$ 185,266	$ 26,777
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense															266,096			$ 448,189
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value			$ 199,921									$ 566,483			$ 39,200
Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized								1,000,000																			1,000,000
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Shares and warrants issued for cash (in shares)															180,167			433,600	42,030
Warrants to purchase common stock															56,290
Warrants aggregate grant date fair value															$ 188,883
Minimum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share																		$ 5	$ 17
Warrants exercise price																		$ 6	$ 30
Estimated Forfeitures Related To Option Grants Annual Rate																		0.00%	0.00%
Minimum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price												$ 10.60
Minimum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																													300,000
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price															$ 8
Estimated Forfeitures Related To Option Grants Annual Rate															0.00%
EquityIssuance Per Share Value															$ 5
Maximum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share																		$ 9	$ 30
Warrants exercise price																		$ 15	$ 80
Estimated Forfeitures Related To Option Grants Annual Rate																		5.00%	5.00%
Maximum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price												$ 13
Maximum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																													600,000
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price															$ 15
Estimated Forfeitures Related To Option Grants Annual Rate															5.00%
EquityIssuance Per Share Value															$ 6

Black-Scholes Option Pricing Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) - Warrants	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.22%	0.39%	0.39%	0.34%
Expected term (years)		1 year 11 months 16 days	1 year 11 months 16 days	3 years
Expected volatility	121.00%	120.00%	116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.71%	2.20%	2.20%	1.68%
Expected term (years)		5 years	5 years	5 years
Expected volatility	122.00%	129.00%	122.00%	135.00%

Summary of Warrant Activity (De

Summary of Warrant Activity (Detail) - Warrants - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014		Dec. 31, 2013
Number of Warrants
Beginning Balance	412,423	239,792		166,740
Granted	316,428	192,463		157,357
Exercised	0	(18,832)		(84,305)
Forfeited	0	(1,000)		0
Ending Balance	728,850	412,423		239,792
Exercisable	693,850	377,422
Weighted Average Exercise Price
Beginning Balance	$ 17.97	$ 24.16		$ 33.80
Granted	13.82	13.92		31.20
Exercised	0	6	[1]	6	[1]
Forfeited	0	10		0
Ending Balance	16.17	17.97		$ 24.16
Exercisable	$ 15.47	$ 16.86
Weighted Average Remaining Life In Years
Outstanding	3 years 9 months 18 days	3 years 2 months 12 days
Exercisable	3 years 10 months 24 days	3 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 45,500	$ 0
Exercisable	$ 45,500	$ 0
[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 84,305 shares of common stock, with original exercise prices ranging from $30.00 to $80.00 per share, had their exercise prices reduced to $6.00 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 18,832 shares of common stock, with original exercise prices ranging from $30.00 to $80.00 per share, had their exercise prices reduced to $6.00 per share pursuant to the Warrant Exercise and Reload Program.

Summarized Information Related

Summarized Information Related to Stock Warrants (Detail) - $ / shares		6 Months Ended	12 Months Ended
		Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants		728,850	412,423
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		693,850	377,422	[1]
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 6	$ 6
Warrants Outstanding, Number of Warrants		32,500	32,500
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		32,500	32,500
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 7.60	$ 8
Warrants Outstanding, Number of Warrants		25,000	10,000
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 9 months 18 days	4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		25,000	10,000
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 8	$ 10
Warrants Outstanding, Number of Warrants		12,500	25,104
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 6 months	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		12,500	25,104
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 10	$ 10.60
Warrants Outstanding, Number of Warrants		56,554	19,000
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 7 months 6 days	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		56,554	19,000
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 10.60	$ 11.60
Warrants Outstanding, Number of Warrants		19,000	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 10 months 24 days	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		19,000	2,500
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 11.60	$ 15
Warrants Outstanding, Number of Warrants		2,500	202,160
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 3 months 18 days	2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		2,500	202,160
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 12	$ 18.80
Warrants Outstanding, Number of Warrants		5,000	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 9 months 18 days	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		5,000	2,500
Exercise Price 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 15	$ 20
Warrants Outstanding, Number of Warrants		454,638	27,500
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		454,638	27,500
Exercise Price 9
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 18.80	$ 30
Warrants Outstanding, Number of Warrants		2,500	43,140
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 3 months 18 days	2 years 6 months
Warrants Exercisable, Exercisable Number of Warrants		2,500	43,140
Exercise Price 10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 20	$ 35
Warrants Outstanding, Number of Warrants		27,500	1,000
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days	2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		27,500	1,000
Exercise Price 11
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 30	$ 40
Warrants Outstanding, Number of Warrants		43,140	6,176
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years	3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		43,140	6,176
Exercise Price 12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 35	$ 50
Warrants Outstanding, Number of Warrants		1,000	1,000
Warrants Exercisable, Weighted Average Remaining Life In Years		1 year 9 months 18 days	2 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants		1,000	1,000
Exercise Price 13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 40	$ 60
Warrants Outstanding, Number of Warrants		6,176	1,843
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 4 months 24 days	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		6,176	1,842
Exercise Price 14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 50	$ 80
Warrants Outstanding, Number of Warrants		1,000	3,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 1 month 6 days	2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		1,000	3,000
Exercise Price 15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 60
Warrants outstanding, Exercise Price Description			Variable
Warrants Outstanding, Number of Warrants		1,842	35,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 9 months 18 days	0 years	[1]
Warrants Exercisable, Exercisable Number of Warrants		1,842	0	[1]
Exercise price 16
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 80
Warrants Outstanding, Number of Warrants		3,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		3,000
Exercise Price 17
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	[2]
Warrants Outstanding, Number of Warrants		35,000
Warrants Exercisable, Weighted Average Remaining Life In Years		0 years
Warrants Exercisable, Exercisable Number of Warrants		0
[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
[2]	Warrants to purchase 35,000 shares of common stock have an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2015.

Black-Scholes Option Pricing 49

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) - Stock Options	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.33%	1.50%	1.50%	1.13%
Expected term (years)	5 years	5 years	5 years	5 years
Expected volatility	121.00%	120.00%	116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.64%	2.54%	2.54%	2.66%
Expected term (years)	6 years	10 years	10 years	10 years
Expected volatility	122.00%	121.00%	122.00%	135.00%

Information Related to Stock Op

Information Related to Stock Option Expense (Detail) - Stock Options - USD ($)	6 Months Ended			12 Months Ended
	Jun. 30, 2015		Jun. 30, 2014	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 484,526		$ 510,268	$ 874,193		$ 647,815
Unrecognized expense	$ 1,883,801			$ 2,328,885
Weighted Average Amortization Period (Years)	2 years 2 months 12 days			2 years 7 months 6 days
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 118,230		251,575	$ 365,825		160,894
Unrecognized expense	$ 476,246			$ 654,956
Weighted Average Amortization Period (Years)	2 years 3 months 18 days			2 years 7 months 6 days
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 233,152		153,714	$ 328,740		251,758
Unrecognized expense	$ 643,481	[1]		$ 712,551	[2]
Weighted Average Amortization Period (Years)	2 years 2 months 12 days			2 years 6 months
General and administrative
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 133,144		$ 104,979	$ 179,628		$ 235,163
Unrecognized expense	$ 764,074			$ 961,378
Weighted Average Amortization Period (Years)	2 years 2 months 12 days			2 years 7 months 6 days
[1]	Includes $266,096 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
[2]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.

Summary of Stock Option Activit

Summary of Stock Option Activity (Detail) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Feb. 20, 2014	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Options
Outstanding		779,200	252,150	200,900
Granted	25,000	45,000	528,750	57,250
Exercised		0	0	0
Forfeited		(35,000)	(1,700)	(6,000)
Outstanding		789,200	779,200	252,150
Exercisable		365,327	318,573
Weighted Average Exercise Price
Outstanding		$ 12.18	$ 20.70	$ 22.40
Granted	$ 6.40	8.82	8.17	13.60
Exercised		0	0	0
Forfeited		6.34	26.18	10
Outstanding		12.25	12.18	$ 20.70
Exercisable		$ 17.49	$ 18.29
Weighted Average Remaining Life In Years
Outstanding		8 years	8 years 6 months
Exercisable		7 years 2 months 12 days	7 years 7 months 6 days
Intrinsic Value
Outstanding		$ 317,000	$ 979,600
Exercisable		$ 28,500	$ 45,600

Information Related to Stock 52

Information Related to Stock Options (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	789,200	779,200
Options Exercisable, Weighted Average Remaining Life In Years	7 years 2 months 12 days	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	365,327	318,573
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 5.70	$ 5.70
Options Outstanding, Number of Options	35,000	45,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years	9 years 6 months
Options Exercisable, Exercisable Number of Options	15,000	10,000
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.40	$ 6.40
Options Outstanding, Number of Options	25,000	25,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years	0 years
Options Exercisable, Exercisable Number of Options	0	0
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.60	$ 6.60
Options Outstanding, Number of Options	281,250	306,250
Options Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days	4 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	3,750	3,750
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.80	$ 6.80
Options Outstanding, Number of Options	12,500	12,500
Options Exercisable, Weighted Average Remaining Life In Years	0 years	0 years
Options Exercisable, Exercisable Number of Options	0	0
Exercise Price 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 7.80	$ 7.80
Options Outstanding, Number of Options	3,000	3,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years	4 years 6 months
Options Exercisable, Exercisable Number of Options	3,000	3,000
Exercise Price 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 8	$ 10
Options Outstanding, Number of Options	15,000	17,250
Options Exercisable, Weighted Average Remaining Life In Years	0 years	4 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	0	16,625
Exercise Price 7
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.20	$ 10.60
Options Outstanding, Number of Options	25,000	2,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	0	2,000
Exercise Price 8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.40	$ 12
Options Outstanding, Number of Options	5,000	49,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 7 months 6 days	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	4,375	49,000
Exercise Price 9
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10	$ 13
Options Outstanding, Number of Options	17,250	133,750
Options Exercisable, Weighted Average Remaining Life In Years	4 years 4 months 24 days	9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	17,250	56,248
Exercise price 10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10.60	$ 20
Options Outstanding, Number of Options	2,000	6,550
Options Exercisable, Weighted Average Remaining Life In Years	8 years 8 months 12 days	8 years
Options Exercisable, Exercisable Number of Options	2,000	6,550
Exercise Price 11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 12	$ 21
Options Outstanding, Number of Options	49,000	113,500
Options Exercisable, Weighted Average Remaining Life In Years	8 years 3 months 18 days	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	49,000	113,500
Exercise Price 12
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 13	$ 22
Options Outstanding, Number of Options	133,750	250
Options Exercisable, Weighted Average Remaining Life In Years	8 years 3 months 18 days	2 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	92,502	250
Exercise Price 13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 20	$ 24
Options Outstanding, Number of Options	6,550	500
Options Exercisable, Weighted Average Remaining Life In Years	7 years 6 months	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options	6,550	500
Exercise Price 14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 21	$ 25
Options Outstanding, Number of Options	113,500	2,150
Options Exercisable, Weighted Average Remaining Life In Years	6 years 7 months 6 days	1 year 10 months 24 days
Options Exercisable, Exercisable Number of Options	113,500	2,150
Exercise Price 15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 22	$ 28
Options Outstanding, Number of Options	250	17,500
Options Exercisable, Weighted Average Remaining Life In Years	2 years	4 years 6 months
Options Exercisable, Exercisable Number of Options	250	10,000
Exercise price 16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 24	$ 30
Options Outstanding, Number of Options	500	45,000
Options Exercisable, Weighted Average Remaining Life In Years	10 months 24 days	7 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	500	45,000
Exercise Price 17
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 25
Options Outstanding, Number of Options	2,150
Options Exercisable, Weighted Average Remaining Life In Years	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options	2,150
Exercise price 18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 28
Options Outstanding, Number of Options	17,500
Options Exercisable, Weighted Average Remaining Life In Years	4 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	10,500
Exercise price 19
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 30
Options Outstanding, Number of Options	45,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	45,000

Information Related to Common S

Information Related to Common Stock Award Expense (Detail) - Common Stock Award - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 99,147	$ 240,398	$ 300,837	$ 138,055
Unrecognized expense	0		0
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	90,300	234,500	276,500	111,351
Unrecognized expense	0		0
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	8,847	$ 5,898	24,337	$ 26,704
Unrecognized expense	$ 0		$ 0

Summary of Common Stock Award A

Summary of Common Stock Award Activity (Detail) - Common Stock Award - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	0	0
Number of Shares, Granted	97,188	11,977
Number of Shares, Vested	(97,188)	(11,977)
Numberof Shares, Forfeited	0	0
Number of Shares, Ending Balance	0	0
Weighted Average Grant Date Fair Value, Beginning Balance	$ 0	$ 0
Weighted Average Grant Date Fair Value, Granted	5.27	11.53
Weighted Average Grant Date Fair Value, Vested	(5.27)	(11.53)
Weighted Average Grant Date Fair Value, Forfeited	0	0
Weighted Average Grant Date Fair Value, Ending Balance	$ 0	$ 0
Total Grant Date Fair Value, Beginning Balance	$ 0	$ 0
Total Grant Date Fair Value, Granted	511,886	138,055
Total Grant Date Fair Value, Vested	(511,886)	(138,055)
Total Grant Date Fair Value, Forfeited	0	0
Total Grant Date Fair Value, Ending Balance	$ 0	$ 0

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) - USD ($)

Oct. 14, 2015

Aug. 13, 2015

Aug. 07, 2015

Jul. 09, 2015

Jul. 07, 2015

Apr. 06, 2015

Mar. 09, 2015

Feb. 09, 2015

Oct. 07, 2014

Aug. 13, 2014

Oct. 21, 2015

Sep. 29, 2015

Aug. 19, 2015

Jul. 27, 2015

Jan. 23, 2015

Sep. 24, 2014

Jul. 27, 2014

Jul. 23, 2014

Jun. 27, 2014

Jun. 16, 2014

Feb. 20, 2014

Mar. 26, 2013

Jun. 30, 2015

Dec. 31, 2014

Dec. 31, 2013

Oct. 15, 2015

Aug. 21, 2015

May. 29, 2015

May. 27, 2015

Dec. 02, 2014

May. 08, 2014

May. 02, 2014

Dec. 18, 2013

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

10.00%

Number of shares called by warrants

41,549

9,500

20,125

Warrants Issued During Period, Number of Warrants

526,250

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

25,000

45,000

528,750

57,250

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$ 6.40

$ 8.82

$ 8.17

$ 13.60

Stock Issued During Period, Shares, New Issues

27,500

Stock Issued During Period, Value, New Issues

$ 1,051,000

$ 2,605,000

$ 905,000

Stock Issued During Period, Shares, Issued for Services

8,500

Stock Issued During Period, Value, Issued for Services

$ 2,420

Debt Instrument, Face Amount

$ 4,000,000

7,500

Class of Warrant or Right, Outstanding

5,000

Received non-interest bearing advances from officer

60,055

Repayments Short Term Advances

$ 60,055

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 15

Debt Conversion, Original Debt, Amount

$ 30,000

Advisory Services [Member] | Extension One [Member]

Subsequent Event [Line Items]

Warrant Issued To Purchase Common Stock

12,500

Additional Monthly Fee For Services Rendered

$ 16,667

Advisory Services [Member] | Extension Two [Member]

Subsequent Event [Line Items]

Warrant Issued To Purchase Common Stock

5,000

Additional Monthly Fee For Services Rendered

$ 15,000

Bermuda Lender [Member]

Subsequent Event [Line Items]

Number of shares called by warrants

186,682

Stock Issued During Period, Shares, New Issues

30,000

Stock Issued During Period, Value, New Issues

$ 480,000

Debt Instrument, Face Amount

$ 4,410,937

Debt Instrument, Interest Rate, Effective Percentage

11.00%

15.00%

Interest Payable

$ 69,436

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 15

Bermuda Lender [Member] | Research and Development Arrangement [Member]

Subsequent Event [Line Items]

Debt Instrument Prepayments of Debt

266,297

Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

$ 105,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 15

$ 50

Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

$ 90,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

$ 18.80

Consultant

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

3,750

3,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$ 6.60

$ 7.80

Stock Issued During Period, Shares, Issued for Services

1,500

Stock Issued During Period, Value, Issued for Services

$ 33,000

Director [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

15,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$ 8

Received non-interest bearing advances from officer

$ 202,490

Repayments Short Term Advances

$ 105,490

Warrant Issued To Purchase Common Stock

30,000

Exchangeable Notes Payable

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

10.00%

12.00%

12.00%

Number of shares called by warrants

17,700

Debt Instrument, Face Amount

$ 315,000

Proceeds from Convertible Debt

$ 75,000

Debt Instrument, Interest Rate, Effective Percentage

100.00%

Debt Instrument, Increase, Accrued Interest

$ 3,646

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

Debt Conversion, Original Debt, Amount

$ 158,333

Debt Conversion, Converted Instrument, Shares Issued

3,600

Debt Instrument, Convertible, Terms of Conversion Feature

The convertible notes are convertible into shares of the Company's common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 62% to 65% of the fair value of the Company's common stock or (b) $3.00 per share.

Exchangeable Notes Payable | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

12.00%

Debt Instrument, Convertible, Conversion Price

$ 5.16

$ 4.40

Exchangeable Notes Payable | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

10.00%

Debt Instrument, Convertible, Conversion Price

$ 4.44

$ 3.80

Officer [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 75,000

Proceeds from Issuance of Debt

$ 65,000

Subsequent Event

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

12.00%

Warrants Issued During Period, Number of Warrants

5,000

Warrants Issued During Period, Exercise Price

$ 9.40

Sale of Stock, Price Per Share

$ 5

Debt Instrument, Face Amount

$ 840,000

$ 60,000

$ 460,000

$ 50,000

$ 150,000

Proceeds from Convertible Debt

$ 30,000

Debt Instrument, Convertible, Conversion Price

$ 2

Interest Payable

$ 70,727

$ 6,951

Class of Warrant or Right, Outstanding

24,500

Debt Instrument Percentage For Fair Value

55.00%

Debt Instrument, Increase, Accrued Interest

$ 5,984

Sale of Stock, Number of Shares Issued in Transaction

11,113

Severance Payment

$ 125,000

Warrant Issued To Purchase Common Stock

4,000

Investment Warrants, Exercise Price

$ 15

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4

$ 4

$ 10

Debt Conversion, Converted Instrument, Shares Issued

227,682

116,738

Debt Conversion, Converted Instrument, Warrants or Options Issued

227,682

116,738

Warrant Expiration Term

5 years

5 years

Subsequent Event | Advisory Services [Member] | Extension One [Member]

Subsequent Event [Line Items]

Warrant Issued To Purchase Common Stock

10,000

Investment Warrants, Exercise Price

$ 12

Additional Monthly Fee For Services Rendered

$ 15,000

Subsequent Event | Advisory Services [Member] | Extension Two [Member]

Subsequent Event [Line Items]

Warrant Issued To Purchase Common Stock

10,000

Investment Warrants, Exercise Price

$ 10

Subsequent Event | Employee Stock Option [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

25,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$ 9.20

Subsequent Event | In Process Research and Development [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

$ 177,234

Subsequent Event | Exchange Contingency [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 380,000

Interest Payable

$ 63,776

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4

Debt Conversion, Converted Instrument, Shares Issued

110,944

Debt Conversion, Converted Instrument, Warrants or Options Issued

110,944

Warrant Expiration Term

5 years

Subsequent Event | Japanese Pharmaceutical Company [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

$ 50,000

Subsequent Event | Maximum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

8.75

$ 15

Class of Warrant or Right, Exercise Price of Warrants or Rights

18.80

Subsequent Event | Minimum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

7

$ 8

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 11.60

Subsequent Event | Consultant | Immediately Vesting [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

201,750

Subsequent Event | Consultant | Vesting Over Two Years [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

317,000

Subsequent Event | Consultant | Vesting Over Three Months [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

7,500

Subsequent Event | Chief Executive Officer [Member]

Subsequent Event [Line Items]

Annual Salary

$ 400,000

Description for annual bonus of each year

The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary

Description for Chief Executive Officer receive severance amount one

the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus).

Description for Chief Executive Officer receive severance amount two

the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).

Subsequent Event | Chief Executive Officer [Member] | Maximum [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

2,000,000

Subsequent Event | Chief Executive Officer [Member] | Minimum [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

1,000,000

Subsequent Event | Exchangeable Notes Payable

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 100,000

$ 30,000

Proceeds from Convertible Debt

$ 50,000

Debt Instrument, Interest Rate, Effective Percentage

1.00%

10.00%

Debt Instrument, Convertible, Conversion Price

$ 4.89

Debt Conversion Original Debt Accrued Interest Amount

$ 1,736

Debt Conversion, Original Debt, Amount

$ 30,000

Debt Conversion, Converted Instrument, Shares Issued

6,490

Debt Instrument, Convertible, Terms of Conversion Feature

The convertible note is payable as follows: (i) $20,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the August Note First Maturity Date), (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the August Note First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the August Note First Maturity Date. Each $20,000 of principal and the respective accrued interest on such principal is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Companys stock or (b) $3.00 per share.

This note and the accrued interest are convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Companys stock or $3.00 per share

The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the July Note First Maturity Date), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the July Note First Maturity Date, (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the July Note First Maturity Date and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the July Note First Maturity Date. Each $25,000 of principal and the respective accrued interest on such principal is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Companys stock or (b) $3.00 per share.

This note and the accrued interest are convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Companys stock or $3.00 per share

This note and the accrued interest is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Companys stock or $3.00 per share

Subsequent Event | Six Months Note Payable

Subsequent Event [Line Items]

Number of shares called by warrants

50,000

1,885

Debt Instrument, Face Amount

$ 50,000

$ 50,000

Debt Instrument, Interest Rate, Effective Percentage

10.00%

10.00%

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

$ 10

Subsequent Event | Two Month Notes Payable

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 84,018

Accounts Payable, Interest-bearing

$ 70,015

Subsequent Event | Investor

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

53,633

Stock Issued During Period, Value, New Issues

$ 335,000

Subsequent Event | Investor | Maximum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$ 7

Class of Warrant or Right, Exercise Price of Warrants or Rights

15

Subsequent Event | Investor | Minimum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

4

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 6

Subsequent Event | Investors [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

42,542

Stock Issued During Period, Shares, New Issues

135,167

Stock Issued During Period, Value, New Issues

$ 801,000

Subsequent Event | Investors [Member] | Maximum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$ 9.20

Subsequent Event | Investors [Member] | Minimum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$ 5

Subsequent Event | Consultants [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

13,515

Stock Issued During Period, Value, Issued for Services

$ 73,528

Subsequent Event | Consultants [Member] | Immediately Vesting [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

625

Subsequent Event | Consultants [Member] | Vesting Over One Year [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

625

Subsequent Event | Consultants [Member] | Vesting Over Three Months [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

3,750

Subsequent Event | Lenders [Member] | Exchangeable Notes Payable

Subsequent Event [Line Items]

Number of shares called by warrants

3,300

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

Subsequent Event | Lenders [Member] | Six Months Note Payable

Subsequent Event [Line Items]

Number of shares called by warrants

1,500

1,500

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10

$ 10